Poster Session A Sunday, September 25 5:00 p.m. … Documents/IMM16_AbstractTitles.pdf · Sebastian...

Poster Session A Sunday, September 25

5:00 p.m.-7:30 p.m. Posters A001-A075, Americas Hall I/Posters A076 –A148, Americas Hall II

A001 Tumor-specific mutant antigens in cancer immunotherapy. Matthew M. Gubin

1, Jeffrey P. Ward

1, Takuro

Noguchi1, Xiuli Zhang

1, Cora Arthur

1, Willem-Jan Krebber

2, Gwenn E. Mulder

2, Cornelis J.M. Melief

2, William E.

Gillanders1, Maxim Artyomov

1, Elaine R. Mardis

1, Robert D. Schreiber

1.

1Washington University School of Medicine,

Saint Louis, MO; 2ISA Therapeutics B.V., Leiden, Netherlands.

A002 T cell responses to peptide-epitopes of choice can be boosted by immune complexes of circulating anti-tetanus toxoid antibodies. E. Fletcher

1, W. van Maren

2, R. Cordfunke

2, J. Dinkelaar

3, R. Castelli

3, JDC Codee

3, G. van

der Marel3, CJM Melief

2, JW Drijfhout

2, F. Ossendorp

2, SM Mangsbo

1.

1Department of Immunology, Genetics and

Pathology, Uppsala University, Uppsala, Sweden; 2Department of Immunohematology & Blood Transfusion, Leiden

University Medical Center, Leiden, Netherlands; 3Department of Bio-organic Synthesis, Leiden University, Leiden,

Netherlands. A003 A personalized neoantigen vaccine in patients with high risk melanoma. Patrick A. Ott

1, Zhuting Hu

1, Derin

B. Keskin1, Sachet A. Shukla

1, Jing Sun

1, Ed Fritsch

2, Nir Hacohen

3, Catherine J. Wu

1.

1Dana Farber Cancer Institute,

Boston, MA; 2Neon Therapeutics, Cambridge, MA;

3Broad Institute of MIT and Harvard, Cambridge, MA.

A004 Systemic RNA vaccines: Connecting effective cancer immunotherapy with antiviral defense mechanims. Lena M. Kranz

1, Mustafa Diken

1, Heinrich Haas

2, Sebastian Kreiter

1, Carmen Loquai

3, Kerstin C.

Reuter2, Martin Meng

2, Daniel Fritz

2, Fulvia Vascotto

1, Hossam Hefesha

2, Christian Grunwitz

4, Mathias Vormehr

4,

Yves Hüsemann2, Abderraouf Selmi

1, Andreas N. Kuhn

2, Janina Buck

2, Evelyna Derhovanessian

5, Richard Rae

1,

Sebastian Attig1, Jan Diekmann

2, Robert A. Jabulowsky

2, Sandra Heesch

2, Jessica Hassel

6, Peter Langguth

7, Stephan

Grabbe3, Christoph Huber

1, Özlem Türeci

8, Ugur Sahin

1.

1TRON-Translational Oncology Mainz, Mainz, Germany;

2BioNTech RNA Pharmaceuticals, Mainz, Germany;

3University Medical Center of the Johannes Gutenberg

University Mainz, Mainz, Germany; 4Research Center for Immunotherapy (FZI), University Medical Center at the

Johannes Gutenberg University Mainz, Mainz, Germany; 5BioNTech, Mainz, Germany;

6Heidelberg University

Hospital, Heidelberg, Germany; 7Johannes Gutenberg University Mainz, Mainz, Germany;

8Cluster for

Individualized Immune Intervention, Mainz, Germany. A005 Tumor- and host-intrinsic RIG-I signaling promote anticancer immunity by CTLA-4 blockade. Simon Heidegger

1, Alexander Wintges

1, Diana Kreppel

1, Sarah Bek

1, Michael Bscheider

2, Martina Schmickl

1, Marcel R.M.

van den Brink3, Christian Peschel

1, Tobias Haas

1, Hendrik Poeck

1.

1Klinikum rechts der Isar, TU Munich, Munich,

Germany; 2Stanford University School of Medicine, Stanford, CA;

3Memorial Sloan Kettering Cancer Center, New

York City, NY. A006 Frameshift peptide neoantigens as vaccine targets in microsatellite-unstable cancers. Magnus von Knebel Doeberitz

1, Matthias Kloor

1, Miriam Reuschenbach

1, Claudia Pauligk

2, Mohammad-Reza Rafiyan

2, Salah-Eddin Al

Batran2, Julia Karbach

2, Mirjam Tariverdian

3, Elke Jaeger

2.

1University of Heidelberg, Heidelberg, Germany;

2Krankenhaus Nordwest, UCT University Cancer Center, Frankfurt, Germany;

3Department of Surgery, University

Hospital Heidelberg, Heidelberg, Germany. A007 Intratumoral delivery of inactivated vaccinia virus is more efficacious than live oncolytic vaccinia virus in murine bilateral tumor implantation models. Weiyi Wang, Peihong Dai, Ning Yang, Stewart Shuman, Taha Merghoub, Jedd D. Wolchok, Liang Deng. Memorial Sloan Kettering Cancer Center, New York, NY.



A008 Photochemical internalization: Light-induced enhancement of MHC Class I antigen presentation, giving strong enhancement of cytotoxic T-cell responses to vaccination. Tone Otterhaug

1, Markus Haug

2, Gaute Brede

2,

Monika Håkerud3, Anne Grete Nedberg

3, Victoria Edwards

3, Pål Kristian Selbo

3, Pål Johansen

4, Øyvind Halaas

2,

Anders Høgset1.

1PCI Biotech AS, Oslo, Norway;

2The Norwegian University of Science and Technology, Trondheim,

Norway; 3Oslo University Hospital – The Norwegian Radium Hospital, Oslo, Norway;

4Department of Dermatology,

University Hospital Zürich, Oslo, Switzerland. A009 Benchmarking the foreign antigen space of human malignancies. Maarten Slagter

1, Lorenzo Fanchi

1, Marit

M. van Buuren1, Jorg J A Calis

1, Philip Schouten

1, Sabine Linn

1, Marlous Hoogstraat

1, Arno Velds

1, Hendrik Veelken

2,

Ron M. Kerkhoven1, Andrew Menzies

3, Ludmil B. Alexandrov

3, Michael Stratton

3, Lodewyk Wessels

1, Ton N.

Schumacher1.

1Netherlands Cancer Institute, Amsterdam, Netherlands;

2Leiden University Medical Center, Leiden,

Netherlands; 3Wellcome Trust Sanger Institute, Hinxton, United Kingdom.

A010 A novel DNA vaccine targeting fibroblast activation protein (FAP) breaks tolerance and synergizes with anticancer immune therapy in mice. Elizabeth Duperret

1, Dylan Ammons

1, Megan C. Wise

1, Jian Yan

2, Laurent M.

Humeau2, David B. Weiner

1.

1Wistar Institute, Philadelphia, PA;

2Inovio Pharmaceuticals, Plymouth Meeting, PA.

A011 Tissue profiling reveals lifelong specialization of dendritic cell subsets in humans. Tomer Granot, Takashi Senda, Dustin Carpenter, Donna L. Farber. Columbia University, New York, NY. A012 Combining in situ vaccination with immune checkpoint blockade induces long-term regression of lymphoma tumors. Linda Hammerich

1, Thomas Davis

2, Tibor Keler

2, Andres M. Salazar

3, Joshua D. Brody

1.

1Icahn

school of Medicine at Mount Sinai, New York, NY; 2Celldex Therapeutics, Needham, MA;

3Onovir, Inc, Washington,

DC. A013 Favorable changes in tumor microenvironment following intravenous dosing with live attenuated Listeria monocytogenes-based immunotherapy. Weiwen Deng

1, Takahiro Tsujikawa

2, Nitya Nair

1, Thomas Hudson

1,

Weiqun Liu1, Chris S. Rae

1, Edward E. Lemmens

1, Anthony W. Desbien

1, William Hanson

1, Peter Lauer

1, Lisa M.

Coussens2, Dirk G. Brockstedt

1, Thomas W. Dubensky, Jr.

1, Meredith L. Leong

1.

1Aduro Biotech, Berkeley, CA;

2Oregon Health Sciences University, Portland, OR.

A014 CIITA dependent MHC class II IA expression in tumor cells triggers CD4 T cell protective and long lasting antitumor immunity. Farah Bou Nasser Eddine, Greta Forlani, Giovanna Tosi, Roberto S. Accolla. University of Insubria, Varese, Italy. A015 Protein arginine deiminase enzymes which citrullinate epitopes for MHC II presentation are independent predictors of survival in colorectal cancer. R. Metheringham, M. Gijon, I. Daniels, K. Cook, P. Symonds, T. Pitt, W. Xue, V. Brentville, L. Durrant. Scancell Limited, Nottingham, United Kingdom. A016 Multipotency of a CD40L-expressing recombinant vaccinia virus. Emanuele Trella. University Hospital Basel, Basel, Switzerland. A017 Method for molecular characterization of antigens, epitopes and T cell receptors for adoptive CD4 immunotherapy. Milosevic Slavoljub, Ellinger Christian, Wehner Carina, Raffegerst Silke, Wilde Susanne, Weis Manon, Sailer Nadja, Schendel Dolores. Medigene, Planegg/Martinsried, Germany.



A018 High-value T cell epitope selection for mutanome-directed cancer immunotherapy using an innovative cancer neo-epitope classification system. Lenny Moise, Guilhem Richard, Frances Terry, William Martin, Anne De Groot. EpiVax Inc, Providence, RI. A019 Chimeric antigen receptors (CARs) as a low-impact treatment of pediatric ependymomas. Laura K. Donovan

1, Kevin J. Bielamowicz

2, Alex Manno

1, Nabil Ahmed

2, Michael D. Taylor

1.

1The Hospital for Sick Children,

Toronto, ON, Canada; 2Baylor College of Medicine, Houston, TX.

A020 A novel synthetic CD40L plasmid adjuvant generates unique anti-HPV DNA vaccine induced responses that impact tumor growth. Megan C. Wise

1, Elizabeth K. Duperret

1, Daniel O. Villarreal

2, Lumena Louis

1, Jian Yan

3,

Matthew P. Morrow3, Laurent M. Humeau

3, Niranjan Y. Sardesai

3, David B. Weiner

1.

1Wistar Insititute,

Philadelphia, PA; 2University of Pennsylvania, Philadelphia, PA;

3Inovio Pharmaceuticals, Plymouth Meeting, PA.

A021 Development of an ALK vaccine to treat ALK-rearranged non-small cell lung cancers. Rafael B. Blasco. Boston Children´s Hospital, Boston, MA. A022 Computational pipeline for a personalized genomic vaccine trial. Alexander Rubinsteyn

1, Isaac Hodes

1,

Sebastien F. Mondet1, John P. Finnigan

1, Philip Friedlander

2, Rachel Sabado

1, Nina Bhardwaj

1, Jeffrey

Hammerbacher1.

1Icahn School of Medicine at Mount Sinai School, New York, NY;

2Mount Sinai Hospital, New York,

NY. A023 Inducing neoantigens in disseminated tumor lesions to enhance their susceptibility to PD-1 blockade therapy. Greta Garrido Hidalgo, Agata Levay, Alexey Berezhnoy, Brett Schrand, Eli Gilboa. University of Miami, Miami, FL. A024 Predicting cancer survival with neo-epitope burden. Nicholas K. Akers, Eric Schadt, Bojan Losic. Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY. A025 Association of functionally distinct ERAP1 variants in HPV positive cancer. Emma Reeves, Emma King, Tim Elliott, Gareth Thomas, Edward James. University of Southampton, Southampton, United Kingdom. A026 Tumor-specific glycosylated CD43 is a novel and highly specific target for acute myeloid leukemia and myelodysplastic syndrome. Marijn Gillissen

1, Martijn Kedde

2, Etsuko Yasuda

2, Greta De Jong

1, Sophie Levie

2, Arjen

Bakker2, Paul Hensbergen

3, Julien Villaudy

2, Tim Beaumont

2, Pauline van Helden

1, Hergen Spits

2, Mette D.

Hazenberg1.

1Academic Medical Center, Amsterdam, Netherlands;

2AIMM Therapeutics, Amsterdam, Netherlands;

3Leiden University Medical Center, Leiden, Netherlands.

A027 HLA-DP restricted responses to citrullinated proteins are pre-existing in the memory pool and can be rapidly reactivated to provide good tumor therapy. Victoria Brentville

1, Rachael Metheringham

1, Ian Daniels

1,

Katherine Cook1, Peter Symonds

1, Tracy Pitt

1, Wei Xue

1, Mohamed Gijon

1, Lindy Durrant

2.

1Scancell Ltd,

Nottingham, United Kingdom; 2Nottingham University, Nottingham, United Kingdom.

A028 Pre-clinical development of a first-in-class fully synthetic heat shock protein-based personalized cancer vaccine. Mithun Khattar, Antoine Tanne, Benjamin Morin, Nicholas Wilson, Mohamed Uduman, Justin Zelin, Robert Stein, Mark Exley, John Castle, Daniel L. Levey. Agenus Inc., Lexington, MA.



A029 A vaccine-induced, antigen-specific TH9 immune response blocks tumor cell engraftment. Aws Abdul-Wahid, Aaron Prodeus, Marzena Cydzik, Mays Alwash, Jean Gariepy. University of Toronto, Toronto, ON, Canada. A030 Development of acid responsive microparticles for cytotoxic T-lymphocyte based antitumor immunotherapy. Xuefei Huang, Herbert Kavunja, Shuyao Lang, Suttipun Sungsuwan, Zhaojun Yin. Michigan State University, East Lansing, MI. A031 Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy. Yared Hailemichael

1, Tihui Fu

1, Amber Woods

2, Jason Roszik

1, Kimberly S. Schluns

1, Victor H. Engelhard

2, Padmanee

Sharma1, Willem W. Overwijk

1.

1UT MD Anderson Cancer Center, Houston, TX;

2University of Virginia School of

Medicine, Charlottesville, VA. A032 Using oncolytic polio expressing tumor as a cancer vaccine. M Mubeen Mosaheb, Elena Dobrikova, Michael C. Brown, Christopher Pirozzi, Vidyalakshmi Chandramohan, Eda Holl, Smita Nair, Matthias Gromeier. Duke University, Durham, NC. A033 Mechanisms that mediate intralocus and interlocus regulation of V(D)J recombination at immunoglobulin light chain loci. Zhaoqing Ba

1, Jiazhi Hu

1, Zhou Du

1, Sherry G. Lin

1, Duane R. Wesemann

2,

Frederick W. Alt1.

1Howard Hughes Medical Institute, Program in Cellular and Molecular Medicine, Children's

Hospital Boston, Department of Genetics, Harvard Medical School, Boston, MA; 2Department of Medicine, Division

of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA. A034 Boosting the efficacy of PD-L1 blockade with oncolytic vaccine for improved antitumor responses in melanoma. Cristian Capasso, Siri Tähtinen, Federica Frascaro, Sara Carpi, Manlio Fusciello, Davide Cardella, Daniela Cropp, Karita Peltonen, Beatriz Martins, Madeleine Sjöberg, Sari Pesonen, Tuuli Ranki, Lukasz Kuryk, Erkko Ylösmäki, Vincenzo Cerullo. Laboratory of Immunovirotherapy, Division of Pharmaceutical Biosciences & Center for Drug Research, University of Helsinki, Helsinki, Finland. A035 Citrullinated α-enolase as a novel target for cancer immunotherapy . Katherine Cook

1, Ian Daniels

1,

Victoria Brentville1, Rachael Metheringham

1, Wei Xue

1, Peter Symonds

1, Tracy Pitt

1, Mohammed Gijon

1, Lindy G.

Durrant2.

1Scancell Ltd, Nottingham, United Kingdom;

2University of Nottingham, Nottingham, United Kingdom.

A036 Somato-germinomics antigens are immunogenic cancer stem cell antigens. Toshihiko Torigoe

1, Yoshihiko

Hirohashi1, Tomohide Tsukahara

1, Takayuki Kanaseki

1, Munehide Nakatsugawa

1, Terufumi Kubo

1, Kochin Vitaly

2.

1Sapporo Medical University School of Medicine, Sapporo, Japan;

2Nagoya University, Nagoya, Japan.

A037 The Agenus Immunogenic Mutation platform (AIM™) generates synthesis-ready blueprints for the AutoSynVax™ vaccine patient-specific neo-antigen vaccine. Mohamed Uduman, Armen Karapetyan, Mithun Khattar, Antoine Tanne, Benjamin Morin, Justin Zelin, Sandra Craig, Shiwen Shiwen, Bishnu Joshi, Mark A. Findeis, Nicholas Wilson, Elise Drouin, Amy Yang, Jeffrey Raizer, John Goldberg, Jennifer Buell, Robert Stein, John Castle, Daniel L. Levey. Agenus Inc., Lexington, MA. A038 Oncolytic virotherapy combination with DC-based immunotherapy for the treatment of melanoma. Zoltan Banki, Iris Koske, Isabel Barnstorf, Christoph Tripp, Patrizia Stoitzner, Nikolaus Romani, Guido Wollmann, Janine Kimpel, Dorothee Holm-von Laer. Medical University Innsbruck, Innsbruck, Austria.



A039 Accurate identification and prioritization of candidate neoantigens from cancer exome sequencing. James White, John Simmons, Sam Angiuoli, Mark Sausen, Sian Jones, Lisa Kann, Manish Shukla, Maria Sevdali, Victor Velculescu, Luis Diaz, Theresa Zhang. Personal Genome Diagnostic, Baltimore, MD. A040 The low antitumor functionality of PD1-positive gp100-specific CD8+ T cell clones isolated from melanoma patients correlates with the presence of CD28 co-stimulatory molecule. Belinda Palermo

1, Ornella

Franzese2, Cosmo Di Donna

1, Mariangela Panetta

1, Isabella Sperduti

1, Antonella Soriani

1, Maria Laura Foddai

1,

Angela Santoni3, Paola Nisticò

1.

1Regina Elena National Cancer Institute, Rome, Italy;

2University of Rome Tor

Vergata, Rome, Italy; 3University of Rome La Sapienza, Rome, Italy.

A041 Preclinical development of a preventive vaccine against ovarian cancer. Nathalie Scholler

1, Paul Stein

1,

Khushboo Sharma1, Claire Repellin

1, Kalika Kamat

1, Travis Harrison

1, Robert H. Shoemarker

2, Shizuko Sei

2, Lidia

Sambucetti1.

1SRI International, Menlo Park, CA;

2Division of Cancer Prevention, NCI, NIH, Bethesda, MD.

A042 Targeting of alpha-enolase (ENO1) as a novel immunotherapeutical strategy for pancreatic cancer. Francesco Novelli, Michela Capello, Michelle Chattaragada, Sammy Ferri Borgogno, Giorgia Mandili, Moitza Principe, Emanuela Mazza, Sara Bulfamante, Roberta Curto, Daniele Giordano, Paola Cappello. University of Turin, Turin, Italy. A043 Discovery to first-in-man studies of a multi-peptide-based hepatocellular carcinoma vaccine adjuvanted with CV8102 (RNAdjuvant

®): HEPAVAC. Andrea Mayer-Mokler

1, Roberto Accolla

2, Yuk T. Ma

3, Regina Heidenreich

4,

Francesco Izzo5, Alfred Koenigsrainer

6, Markus Loeffler

6, Christian Flohr

1, Phillip Mueller

1, Sarah Kutscher

1, Hans-

Georg Rammensee6, Bruno Sangro

7, Sven Francque

8, Danila Valmori

9, Toni Weinschenk

1, Carsten Reinhardt

1, Ulrike

Gnad-Vogt4, Harpreet Singh

1, Luigi Buonaguro

5.

1Immatics, Tuebingen, Germany;

2University of Insubria, Varese,

Italy; 3University of Birmingham, Birmingham, United Kingdom;

4CureVac AG, Tuebingen, Germany;

5National

Cancer Institute, Naples, Italy; 6University of Tuebingen, Tuebingen, Germany;

7University of Navarra, Pamplona,

Spain; 8University of Antwerpen, Antwerpen, Belgium;

9INSERM, Nantes, France.

A044 Immunological effects of a novel RNA-based adjuvant in liver cancer patients. Luisa Circelli

1, Annacarmen

Petrizzo1, Maria Tagliamonte

1, Regina Heidenreich

2, Maria Lina Tornesello

1, Franco M. Buonaguro

1, Luigi

Buonaguro1.

1National Cancer Institute, NAPLES, Italy;

2CureVac AG, Tuebingen, Germany.

A045 Inhibition of tumor growth by combination of metronomic chemotherapy and checkpoint inhibitor with a cancer vaccine. Maria Tagliamonte, Annacarmen Petrizzo, Angela Mauriello, Antonio Luciano, Domenica Rea, Antonio Barbieri, Claudio Arra, Piera Maiolino, Maria Lina Tornesello, Gennaro Ciliberto, Franco M. Buonaguro, Luigi Buonaguro. National Cancer Institute, NAPLES, Italy. A046 Identification and validation of HCC-specific gene transcriptional signature for tumor antigen discovery. Annacarmen Petrizzo

1, Francesca P. Caruso

2, Maria Tagliamonte

1, Maria Lina Tornesello

1, Michele

Ceccarelli2, Valerio Costa

3, Marianna Aprile

3, Roberta Esposito

3, Gennaro Ciliberto

1, Franco M. Buonaguro

1, Luigi

Buonaguro1.

1National Cancer Institute, NAPLES, Italy;

2University of Sannio, BENEVENTO, Italy;

3IGB - CNR, NAPLES,

Italy. A048 CPI-444: A potent and selective inhibitor of A2AR induces antitumor responses alone and in combination with anti-PD-L1 in preclinical and clinical studies. Stephen Willingham, Andrew Hotson, Po Ho, Carmen Choy, Ginna Laport, Ian McCaffery, Richard Miller. Corvus Pharmaceuticals, Burlingame, CA.



A049 HVEM (TNFRSF14) tumor suppressor in immune therapies of follicular lymphoma. Darin Salloum. Memorial Sloan Kettering Cancer Center, New York, NY. A050 Cdk5 disruption attenuates tumor PD-L1 expression via regulation of IFN-γ signaling components and promotes antitumor immunity. Rodney D. Dorand, Jr., Joseph Nthale, Jay T. Myers, Deborah S. Barkauskas, Stefanie Avril, Steven M. Chirieleison, Tej K. Pareek, Derek W. Abbott, Duncan S. Stearns, John J. Letterio, Alex Y. Huang, Agne Petrosiute. Case Western Reserve University, Cleveland, OH. A051 Characterization of IDO1 and TDO2 in pediatric central nervous system tumors. Kristen Lauing, Rishi Lulla, Lijie Zhai, Rintaro Hashizume, Jason Fangusaro, Derek A. Wainwright. Northwestern University Feinberg School of Medicine, Chicago, IL. A052 Characterization of immune regulatory molecules B7-H4, PD-L1, and ICOS in micro-satellite stable (MSS) and micro-satellite instable (MSI) endometrial tumors. Amit Deshpande

1, Whitfield B. Growdon

2, Heather Hirsch

1,

Tong Zi1, Chris Grange

1, Jason Reeves

1, Jennifer Stall

2, Bo Rueda

2, Sriram Sathyanarayanan

1.

1Jounce Therapeutics,

Cambridge, MA; 2Massachusetts General Hospital, Boston, MA.

A053 Targeting ICOS improves immune-mediated control of tumor growth in humanized mice. Aude Burlion1,

Aurélien Corneau2, Gilles Marodon

1.

1CIMI INSERM u1135, Paris, France;

2UPMC, Paris, France.

A054 Inhibition of TGF-beta isoforms 1 and 2 enhances therapeutic tumor vaccine efficacy. Katharine Clark

1,

Faith C. Robertson1, Emma De Ravin

1, Shingo Kato

1, Anja Bloom

1, Amer Mirza

2, Jay A. Berzofsky

1, Masaki Terabe

1.

1NIH, Bethesda, MD;

2Xoma, Berkeley, CA.

A055 Systematic discovery of combinationimmunotherapy targets in vivo. Adam N. Cartwright1, Rong En Tay

2,

Kai W. Wucherpfennig2.

1Dana Farber Cancer Institute, Boston, MA;

2Dana Farber Cancer Institute, Boston, MA.

A056 Identifying the epigenetic code of tumor-specific CD8 T cell dysfunction and therapeutic reprogramming. Mary Philip, Lauren Fairchild, Liping Sun, Agnes Viale, Steven Camara, Ellen Horste, Taha Merghoub, Jedd D. Wolchok, Christina S. Leslie, Andrea Schietinger. Memorial Sloan Kettering Cancer Center, New York, NY. A057 CX3CR1 distinguishes three distinct migratory memory CD8 T cell subsets. Carmen Gerlach

1, E. Ashley

Moseman1, Scott M. Loughhead

1, David Alvarez

1, Anthonie J. Zwijnenburg

1, Lisette Waanders

1, Rohit Garg

1, Juan C.

de la Torre2, Ulrich H. von Andrian

1.

1Harvard Medical School, Boston, MA;

2The Scripps Research Institute, La Jolla,

CA. A058 Selective targeting of T regulatory cells by a TCR-mimic monoclonal antibody specific for foxp3-derived epitopes. Tao Dao

1, Casey Jarvis

1, Andrew C. Scott

1, Tatyana Korontsvit

1, Victoria Zakhaleva

1, Dmitry Pankov

1,

Manuel Direito de Morais Guerrerio1, Melissa Mathias

1, Neal Cheng

2, Cheng Liu

2, David A. Scheinberg

1.

1Memorial

Sloan Kettering Cancer Center, New York, NY; 2Eureka Therapeutics, Inc, Emeryville, CA.

A059 Combinatorial proteomic analysis of the receptor programmed cell death (PD)-1 uncovers new checkpoint modulators. Michael Peled, Adam Mor. NYU School of Medicine, New York, NY.



A060 The effects of tumor-associated calreticulin mutants on antigen presentation. Najla Arshad, Peter Cresswell. Yale University School of Medicine, New Haven, CT. A061 Acute myeloid leukemia patients cured after allogeneic hematopoietic stem cell transplantation generate tumor-specific cytotoxic antibodies that kill AML blasts . Marijn Gillissen

1, Martijn Kedde

2, Greta De Jong

1, Etsuko

Yasuda2, Sophie Levie

2, Arjen Bakker

2, Yvonne Claassen

2, Koen Wagner

2, Julien Villaudy

2, Martino Bohne

2, Dave

Speijer1, Paul Hensbergen

3, Pauline van Helden

2, Tim Beaumont

2, Hergen Spits

2, Mette D. Hazenberg

1.

1Academic

Medical Center, Amsterdam, Netherlands; 2AIMM Therapeutics, Amsterdam, Netherlands;

3Leiden University

Medical Center, Leiden, Netherlands. A062 The effects of cellular context on miR-155 mediated regulation of gene expression. Jing-Ping Hsin

1,

Yuheng Lu2, Christina S. Leslie

2, Alexander Y. Rudensky

1.

1Immunology Program, Sloan Kettering Institute, New

York, NY; 2Computational Biology Program, Sloan Kettering Institute, New York, NY.

A063 Dissecting adipose tissue Treg differentiation and function in metabolism and obesity-associated cancer using TCR transgenic mice. Chaoran Li, Christophe Benoist, Diane Mathis. Harvard Medical School, Boston, MA. A064 IDO1 expression stratifies glioblastoma patient survival and correlates with dominantly immunosuppressive pathways. Lijie Zhai

1, Matthew Genet

1, Erik Ladomersky

1, Kristen Lauing

1, Meijing Wu

1, David

Binder2, Leo Kim

3, Jeremy Rich

3, Craig Horbinski

4, C. David James

5, Jeffrey A. Sosman

6, Orin Bloch

7, Derek A.

Wainwright8.

1Department of Neurological Surgery, Northwestern University, Chicago, IL;

2Department of

Pathology, University of Chicago, Chicago, IL; 3Department of Stem Cell Biology and Regenerative Medicine, Lerner

Research Institute, Cleveland Clinic, Cleveland, OH; 4Department of Neurological Surgery, Department of

Pathology, Northwestern University, Chicago, IL; 5Department of Neurological Surgery, Department of

Biochemistry and Molecular Genetics, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL;

6Division of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern

University, Chicago, IL; 7Department of Neurological Surgery, Robert H. Lurie Comprehensive Cancer Center,

Northwestern University, Chicago, IL; 8Department of Neurological Surgery, Department of Microbiology-

Immunology, Division of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL. A065 Oscillatory genes in lymphocyte retention and egress. Hsin Chen, Timothy Schmidt, Ying Xu, Erick Lu, Jason G. Cyster. UCSF, San Francisco, CA. A066 NF-kB restricts inflammasome activation via elimination of damaged mitochondria. Zhenyu Zhong, Michael Karin. University of California, San Diego, La Jolla, CA. A067 PD-1 blockade enhances OX40 expression on regulatory T-cells and decreases suppressive function through induction of phospho-STAT3 signaling. David M. Woods

1, Rupal Ramakrishnan

2, Andressa L. Sodré

1,

Anders Berglund2, Jeffrey Weber

1.

1NYU Langone Medical Center, New York, NY;

2Moffitt Cancer Center, Tampa,

FL.



A068 Determinants of efficacy in cancer immunovirotherapy. Rūta Veinalde

1, Christian Grossardt

1, Marie-

Claude Bourgeois-Daigneault2, Christof von Kalle

1, Dirk Jaeger

3, Guy Ungerechts

3, Christine E. Engeland

1.

1National

Center for Tumor Diseases Heidelberg, Department of Translational Oncology, German Cancer Research Center, Heidelberg, Germany;

2Ottawa Hospital Research Institute, Centre for Innovative Cancer Research, Ottawa, ON,

Canada; 3National Center for Tumor Diseases Heidelberg, Department of Medical Oncology, Heidelberg, Germany.

A069 Quantification of lymph node transit times reveals differences in the trafficking behavior of regulatory versus conventional CD4

+ T cells. Alexander Tong. Case Western Reserve University, Cleveland, OH.

A070 The role of the centrosome in cytotoxic T cell function . Fella Tamzalit

1, Ariella Kepecs

1, Hisham Bazzi

2,

Kathryn Anderson1, Morgan Huse

1.

1Memorial Sloan Kettering Cancer Center, New York, NY;

2Cluster of Excellence

- Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany. A071 Identification and characterization of long intergenic non-coding RNAs (lincRNAs) governing T cell development and function. Will Bailis

1, Christian Harman

1, Jorge Henao-Mejia

2, Adam Williams

3, Loyall Goff

4, John

Rinn5, Richard Flavell

1.

1Yale University, New Haven, CT;

2University of Pennsylvania, Philadelphia, PA;

3The Jackson

Laboratory, Farmington, CT; 4Johns Hopkins University, Baltimore, MD;

5Harvard University, Cambridge, MA.

A072 Glucose metabolism and O-linked GlcNAcylation in the tissue repair function of Treg cells. Wei Hu, Nicholas Arpaia, Jesse A. Green, Ronald C. Hendrickson, Alexander Y. Rudensky. Memorial Sloan Kettering Cancer Center, New York, NY. A073 Epigenetic regulation of the Cd4 locus. Priya Issuree

1, Kenny Day

2, Dan R. Littman

1.

1NYU School of

Medicine, New York, NY; 2HudsonAlpha Institute for Biotechnology, Alabama, AL.

A074 A Zap70-dependent negative feedback loop governs Lck activation by CD45. Adam H. Courtney, Theresa A. Kadlecek, Byron Au-Yeung, Arthur Weiss. University of California, San Francisco, San Francisco, CA. A075 Preclinical analysis of combinatorial glioblastoma therapy with the prodrug-mediated gene therapy vector AdV-TK and immune checkpoint inhibition in GBM therapy. Maria Carmela Speranza

1, Kazue Kasai

1, Franz

Ricklefs1, Sarah R. Klein

2, Carmela Passaro

1, Hiroshi Nakashima

1, Johanna Kaufmann

1, Agnieszka Bronisz

1, Estuardo

Aguilar-Cordova3, Brian W. Guzik

3, Gordon J. Freeman

2, David A. Reardon

2, Patrick Wen

2, E. Antonio Chiocca

1, Sean

E. Lawler1.

1Harvard Medical School - Brigham and Women's Hospital, Boston, MA;

2Dana-Farber Cancer Institute,

Harvard Medical School, Boston, MA; 3Advantagene Inc., Auburndale, MA.

A076 Cutaneous microbiota drive the accumulation of IL-17A-producing T cells within the lungs. Michael G. Constantinides, Vanessa K. Ridaura, Yasmine Belkaid. National Institute of Allergy and Infectious Diseases, Bethesda, MD. A077 Identifying novel effectors of the gut microbiota that modulate cancer cell killing by CTLs using functional metagenomics. Lior Lobel, Wendy Garret. Harvard T.H. Chan School of Public Health, Boston, MA. A078 Cutaneous microbiota in development of endogenous anti-melanocyte immunity. Ivan Vujkovic-Cvijin

1,

Jacquice Davis1, Rasnik Singh

2, Kristina Lee

2, Zhiya Yu

1, Nicholas Restifo

1, Maria Wei

2, Yasmine Belkaid

1.

1National

Institutes of Health, Bethesda, MD; 2University of California San Francisco, San Francisco, CA.



A079 Bioorthogonal chemical labeling of specific immunomodulatory surface molecules in live commensals. Jason E. Hudak, David Alvarez, Ashwin Skelly, Ulrich H. von Andrian, Dennis L. Kasper. Harvard Medical School, Boston, MA. A080 Balance of commensal bacteria specific Th17 and RORγt

+Treg cells in intestinal homeostasis and

inflammation. Mo Xu1, Yi Yang

2, Maria Pokrovskii

1, Carolina Galan

1, Dan R. Littman

3.

1The Kimmel Center for

Biology and Medicine of the Skirball Institute, New York University School of Medicine, New York, NY; 2Department

of Microbiology & Immunology, Medical University of South Carolina, Charleston, SC; 3The Kimmel Center for

Biology and Medicine of the Skirball Institute, New York University School of Medicine, Howard Hughes Medical Institute, New York, NY. A081 Chemical biology of microbial metabolite targets in host immunity. Yen-Chih Wang. The Rockefeller University, New York, NY. A082 Identification of commensal bacterial strains that provide resistance to L. monocytogenes infection. Simone Becattini, Sohn G. Kim, Rebecca A. Carter, Lilan Ling, Ingrid M. Leiner, Eric G. Pamer. Memorial Sloan Kettering Cancer Center, New York, NY. A083 Molecular profiling of CD8 T cells from autochthonous melanoma identifies Maf as driver of T cell exhaustion. Gregory Verdeil

1, Marilyn Giordano

2, Anne-Marie Schmitt-Verhulst

2, Daniel Speiser

1, Claire Imbratta

1.

1UNIL, Epalinges, Switzerland;

2CIML, Marseille, France.

A084 High OX-40 expression on the tumor immune infiltrate is a prognostic factor of better survival in non-small cell lung cancer. Erminia Massarelli

1, Edwin R. Parra

2, Jaime Rogriguez-Canales

2, Carmen Behrens

2, Lixia

Diao2, Jorge Blando

2, Jing Wang

2, Lauren A. Byers

2, Ignacio I. Wistuba

2, Padmanee Sharma

2, James P. Allison

2, John

V. Heymach2.

1City of Hope Comprehensive Cancer Center, Duarte, CA;

2The University of Texas MD Anderson

Cancer Center, Houston, TX. A085 Immune evasion and PD-1-positive T cell infiltration in DNA mismatch repair-deficient colorectal cancer. Matthias Kloor

1, Jonas Janikovits

1, Julia Krzykalla

2, Axel Benner

2, Niels Grabe

3, Fabian Echterdiek

1, Meike

Mueller1, Sandrina Koerner

1, Aysel Ahadova

1, Magnus von Knebel Doeberitz

1.

1University of Heidelberg,

Heidelberg, Germany; 2Division of Biostatistics, DKFZ Heidelberg, Heidelberg, Germany;

3Hamamatsu Tissue

Imaging and Analysis (TIGA) Center, Bioquant, Heidelberg, Germany. A086 EMT produces an immunosuppressive tumor microenvironment. Limo Chen, Yanyan Lou, Ignacio Wistuba, Stephen Ullrich, Xiao-Feng Qin, Lauren Byers, John Heymach, Don Gibbons. UT MD Anderson Cancer Center, Houston, TX. A087 Quantifying the landscape of immunostimulatory tumoral RNA. Alexander Solovyov

1, Antoine Tanne

1,

Luciana Muniz1, Simona Cocco

2, Remi Monasson

2, Arnold Levine

3, David T. Ting

4, Nina Bhardwaj

1, Benjamin

Greenbaum1.

1Icahn School of Medicine at Mount Sinai, New York, NY;

2Ecole Normale Superieure, Paris, France;

3Institute for Advanced Study, Princeton, NJ;

4Massachusetts General Hospital, Boston, MA.

A088 Immune profiling of inflamed microsatellite stable colorectal cancer. Nicolas Jose Llosa, Franck Housseau, Nicholas Siegel, Kellie N. Smith, Hongni Fan, Robert M. Anders, Dung Le, Luis Diaz, Jr., Cynthia Sears, Drew M. Pardoll. Johns Hopkins Medical Institutes, Baltimore, MD.



A089 Multiparametric immunofluorescence analysis of the tumor microenvironment using CODEX. Julia Kennedy-Darling, Garry P. Nolan, Yury Goltsev, Nikolay Samusik. Stanford University School of Medicine, Stanford, CA. A090 Identify molecular mechanisms that regulate the GMP-AMP synthase (cGAS) activity. Tuo Li, Zhijian J. Chen. UT Southwestern Medical Center, Dallas, TX. A091 Specific myelomonocytic cells heavily infiltrate orthotopic lung tumors and display a hypoxia-driven miRNA expression signature that directs tumor-supporting functions and negatively impacts on clinical outcome. Elisabeth Brabants

1, Lotte Pyfferoen

2, Celine Everaert

2, Simon Tavernier

2, Kelly Heyns

1, Nancy De

Cabooter1, Glenn Wagemans

1, Kim Deswarte

2, Hamida Hammad

1, Olivier De Wever

2, Jo Vandesompele

2, Bart

Lambrecht2, Pieter Mestdagh

2, Karim Vermaelen

1.

1Ghent University Hospital, Ghent, Belgium;

2Ghent University,

Ghent, Belgium. A092 Comprehensive multidimensional analysis of the immune contexture in non-small cell lung cancer. Romain Remark

1, Yonit Lavin

1, Adeeb Rahman

1, Camille Bigenwald

1, Soma Kobayashi

1, Christian Becker

1,

Raja Flores2, Sacha Gnjatic

1, Miriam Merad

1.

1Icahn School of Medicine at Mount Sinai, New York, NY;

2The Mount

Sinai Hospital, New York, NY. A093 Impact of antigen affinity on T cell dysfunction in solid tumors. Mojdeh Shakiba, Mary Philip, Andrea Schietinger. Memorial Sloan Kettering Cancer Center, New York, NY. A094 mPGES1 deletion increases tumor susceptibility to immune suppression. Nune Markosyan, Andrew Rech, Robert Vonderheide. University of Pennsylvania, Philadelphia, PA. A095 Immunosuppressive plasmocytes regulate the development of NASH-induced HCC. Shabnam Shalapour, Michael Karin. UCSD, La Jolla, CA. A096 Myeloid cells are required for pancreatic carcinogenesis and PD-1/PD-L1 checkpoint activation. Yaqing Zhang

1, Ashley Velez-Delgado

1, Esha Mathew

1, Dongjun Li

1, Flor M. Mendez

1, Kevin Flannagan

1, Andrew D. Rhim

1,

Diane M. Simeone1, Gregory L. Beatty

2, Marina Pasca di Magliano

1.

1University of Michigan, Ann Arbor, MI;

2University of Pennsylvania, Philadelphia, PA.

A097 Tumor PDL1 blocks CTL cytotoxicity. Kathleen A. McGuire

1, Vikram R. Juneja

2, Robert T. Manguso

3, Martin

W. LaFleur1, Natalie Collins

3, W. Nicholas Haining

3, Gordon J. Freeman

4, Arlene H. Sharpe

5.

1Harvard Medical

School, Boston, MA; 2Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA;

3Department of

Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Children's Hospital, Harvard Medical School, Boston, MA;

4Harvard Medical School, Department of Medical Oncology, Dana-Farber Cancer

Institute, Boston, MA; 5Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and

Women’s Hospital, Boston, MA.



A098 A role for fibrosis in promoting pro-tumor immune response in breast cancer. Ori Maller

1, Luke

Cassereau1, Allison Drain

1, Brian Ruffell

2, Irene Acerbi

1, Miranda Broz

1, Jennifer Munson

3, Melody Swartz

4,

Matthew Krummel1, Lisa Coussens

5, Valerie Weaver

1.

1UCSF, San Francisco, CA;

2Moffitt Cancer Center, Tampa, FL;

3University of Virginia , Charlottesville, VA;

4University of Chicago, Chicago, IL;

5Oregon Health & Sciences

University, Portland, CA. A099 Inflammation mediates profound changes to the immunopeptidome of melanoma. Katherine Woods

1,

Ralf B. Schittenhelm2, Anthony W. Purcell

2, Andreas Behren

1, Jonathan Cebon

1.

1Olivia Newton-John Cancer

Research Institute, Melbourne, Australia; 2Dept. of Biochemistry and Molecular biology, Monash University,

Melbourne, Australia. A100 Crosstalk between regulatory T cells and tumor-associated dendritic cells controls antitumor immunity in pancreatic cancer. Jung-Eun Jang

1, Cristina H. Hajdu

1, George Miller

1, Michael L. Dustin

2, Dafna Bar-Sagi

1.

1NYU

school of medicine, New York, NY; 2Kennedy Institute, University of Oxford, Oxford, United Kingdom.

A101 Role of TIM-3/Galectin-9 pathway in lung cancer. Yoshihiro Ohue, Koji Kurose, Yumi Nishio, Midori Isobe, Mikio Oka, Eiichi Nakayama. Kawasaki Medical School, Kurashiki, Okayama, Japan. A102 The fat in ovarian cancer: Immune-dependent tumor-promoting effects . Meggy Suarez-Carmona

1, Anita

Heinzelmann1, Nektarios A. Valous

2, Mareike Hampel

1, Anna Berthel

2, Sarah Schott

3, Inka Zörnig

1, Dirk Jäger

1, Niels

Halama1.

1National Center for Tumor Diseases, Heidelberg, Germany;

2Applied Tumor Immunity Clinical

Cooperation Unit, National Center for Tumor Diseases, German Cancer Research Center, Heidelberg, Germany; 3Heidelberg University Hospital, Heidelberg, Germany.

A103 CCR2-CCL2 signaling is essential for macrophage recruitment to gliomas. Alexander D. Bungert, Susan Brandenburg, Matthäus Felsenstein, Ruth M. Urbantat, Annett Müller, Peter Vajkoczy. Department of Neurosurgery, Charité - Universitätsmedizin Berlin, Berlin, Germany. A104 T cell-mediated immune surveillance is inhibited by tumor-intrinsic signaling. Stefani Spranger, Thomas F. Gajewski. The University of Chicago, Chicago, IL. A105 Characterization of adenosine producing B cells in patients with head and neck cancer as well as of the influence of adenosine on B cell function. Sandra S. Jäkle, Cornelia Brunner, Thomas K. Hoffmann, Patrick J. Schuler. Deptartment of Otorhinolaryngology Head and Neck Surgery Ulm University Medical Center, Ulm, Germany. A106 Src family kinases modulate local inflammatory responses via STAT3 and MMP9 in colorectal cancer patients. Antonia Kathryn Roseweir, Arfon GNT Powell, James Park, Donald C. McMillan, Joanne Edwards. University of Glasgow Institute of Cancer Sciences, Glasgow, United Kingdom. A107 Inhibition of CCR2 potentiates the checkpoint inhibitor immunotherapy in pancreatic cancer. Heiyoun Jung, Linda Ertl, Christine Janson, Thomas Schall, Israel Charo. ChemoCentryx, Mountain View, CA.



A108 CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy. Hans Nijman, Fenne Komdeur, Maartje Wouters, Hagma Workel, Kim Brunekreeft, Annechien Plat, Florine Eggink, Bea Wisman, Toos Daemen, Evelien Duiker, Harry Hollema, Marco de Bruyn. University Medical Center Groningen, Groningen, Netherlands. A109 Immune profiling of tumor infiltrating lymphocyte subsets, myeloid cells and HPV status of HNSCC biopsies using multiplex immunofluorescence. Matt Levin

1, Mark Lingen

2, David Schwartz

1, Helen Snyder

1.

1Cell

IDx, San Diego, CA; 2University of Chicago, Chicago, IL.

A110 Detailed resolution analysis reveals spatial heterogeneity of T cell distribution in the invasive margin of colorectal cancer liver metastases. Anna Berthel

1, Inka Zoernig

2, Meggy Suarez-Carmona

2, Christoph Kahlert

3, Fee

Klupp4, Alexis Ulrich

4, Juergen Weitz

3, Dirk Jaeger

1, Halama Niels

2.

1National Center for Tumor Diseases and

German Cancer Research Center, Heidelberg, Germany; 2National Center for Tumor Diseases and University

Hospital Heidelberg, Heidelberg, Germany; 3University Hospital Dresden, Dresden, Germany;

4University Hospital

Heidelberg, Heidelberg, Germany. A111 Distinct immunological landscapes of progressing and regressing solid tumors post anti-PD-1 immunotherapy. Gessa Sugiyarto, Osman Dadas, Tim Elliott, Edward James. The University of Southampton, Southampton, United Kingdom. A112 Manipulating tumor microenvironment for immunotherapy. Haidong Tang, Xiangyan Qiu, Yang Wang, Yang-Xin Fu. UT Southwestern Medical Center, Dallas, TX. A113 The pattern of hMENA isoforms is regulated by TGF-β1 in pancreatic cancer and may predict patient outcome. Roberta Melchionna

1, Pierluigi Iapicca

1, Francesca Di Modugno

1, Paola Trono

1, Isabella Sperduti

2, Matteo

Fassan3, Ivana Cataldo

3, Borislav C. Rusev

3, Rita T. Lawlor

3, Maria Grazia Diodoro

4, Michele Milella

5, Gian Luca

Grazi6, Mina J. Bissell

7, Aldo Scarpa

3, Paola Nisticò

1.

1Tumor Immunology and Immunotherapy Unit, Regina Elena

National Cancer Institute, Rome, Italy; 2Biostatistics and Scientific Direction, Regina Elena National Cancer Institute,

Rome, Italy; 3ARC-NET Research Centre, Dept of Pathology and Diagnostics, University of Verona, Verona, Italy;

4Pathology Unit, Regina Elena National Cancer Institute, Rome, Italy;

5Medical Oncology 1, Regina Elena National

Cancer Institute, Rome, Italy; 6Hepato-pancreato-biliary Surgery Unit, Regina Elena National Cancer Institute,

Rome, Italy; 7Lawrence Berkeley National Laboratory, University of California, Berkeley, CA.

A114 Effect of different standard of care chemotherapeutics on anti-PD-L1 responses in syngeneic mouse tumor models. Rafael Cubas, Marina Moskalenko, Jeanne Cheung, Shiuh-Ming Luoh, Erin McNamara, Marcia Belvin, Jeong Kim, Stephen Gould. Genentech, South San Francisco, CA. A115 Tyrosine kinase inhibitor therapy modulates immune checkpoints and TCR repertoire diversity in chronic myeloid leukemia. Olli Dufva, Tiina Kasanen, Mohamed El Missiry, Judith Klievink, Hanna Lähteenmäki, Satu Mustjoki. University of Helsinki, Helsinki, Finland.



A116 IgG antibody switching and clonal expansion in melanoma and normal skin microenvironments. Louise Saul

1, Kristina M. Ilieva

1, Heather J. Bax

1, Panagiotis Karagiannis

2, Isabel Correa

1, Irene Rodriguez-Hernandez

1,

Debra H. Josephs1, Isabella Tosi

1, Isioma U. Egbuniwe

1, Sara Lombardi

1, Silvia Crescioli

3, Carl Hobbs

3, Federica

Villanova3, Anthony Cheung

1, Jenny LC Geh

4, Ciaran Healy

4, Mark Harries

5, Victoria Sanz-Moreno

3, David Fear

3,

James F. Spicer1, Katie E. Lacy

1, Frank O. Nestle

3, Sophia N. Karagiannis

1.

1King's College London, London, United

Kingdom; 2University Hospital Hamburg Eppendorf, Hamburg, Germany;

3king's College London, London, United

Kingdom; 4Guy’s, King’s, and St. Thomas’ Hospitals, London, United Kingdom;

5Clinical Oncology, Guy’s and St.

Thomas’ NHS Foundation Trust, London, United Kingdom. A117 CXCR1 is required for neutrophil recruitment to wounds and Kras-transformed cells in zebrafish. Davalyn Powell

1, Qing Deng

2, Anna Huttenlocher

1.

1University of Wisconsin-Madison, Madison, WI;

2Purdue University,

West Lafayette, IN. A118 CD103+/PD-1+ T-cells identify a subset of triple-negative breast cancer eligible for targeted checkpoint inhibition. Giulia Bottai, Massimo Roncalli, Libero Santarpia. Humanitas Clinical and Research Institute, Milan, Italy. A119 CCL3 in the tumor microenvironment augments antitumor immune priming in the lymph node. Frederick Allen, Joseph M. Nthale, Saada K. Eid, Peter Rauhe, David Askew, Jay Myers, Alexander Tong, Alex Y. Huang. Case Western Reserve University, Cleveland, OH. A120 The infiltration of Th17 cells in tumor microenvironment negatively correlate with the prognosis of the patients with head and neck squamous cell carcinoma. Jan Boucek, Michal Zabrodsky. Charles University in Prague, Prague, Czech Republic. A121 Analysis of tumor microenvironment identifies pathways predicting response to checkpoint control inhibitors: A case study comparing the immune microenvironment of uveal melanoma vs skin cutaneous melanoma. Ravi Gupta, Nitin Mandloi, Ashwini Patil, Malini Manoharan, Rekha Sathian, Kiran V. Paul, Amitabha Chaudhuri. MedGenome Inc., Foster City, CA. A122 An investigation into potential immune priming of the tumor microenvironment with FOLFOX chemotherapy in locally advanced rectal cancer. Campbell S. Roxburgh, Jinru Shia, Efsevia Vakiani, Tanisha Daniel, Martin R. Weiser. Memorial Sloan Kettering Cancer Center, New York, NY. A123 Modulation of immune cell trafficking into human colorectal cancer by gut microbiota. Eleonora Cremonesi

1, Francesca Amicarella

1, Jesus Francisco Glaus Garzon

2, Valeria Governa

1, Manuele Giuseppe Muraro

1,

Valentina Mele1, Elisabetta Padovan

1, Daniel Oertli

3, Paul Zajac

1, Giulio Cesare Spagnoli

1, Lubor Borsig

2,

Giandomenica Iezzi1.

1University of Basel, Basel, Switzerland;

2University of Zürich, Zürich, Switzerland;

3University

Hospital Basel, Basel, Switzerland. A124 Protumoral effects of TLR7 in lung tumors. Marion Dajon

1, Kristina Iribarren

1, Isabelle Cremer

2.

1INSERM

UMRS1138, Centre de Recherche des Cordeliers, Paris, France; 2INSERM UMRS1138, Centre de Recherche des

Cordeliers, Paris, France.



A125 Unbiased characterization of CD4

+-T-helper-cell subsets leads to novel understanding heterogeneity and

plasticity of tumor infiltrating lymphocytes. Sophie L.G. Kollbeck, Julia -K. Baukloh, Leonie Brockmann, Babett Steilich, Theodora Agalioti, Samuel Huber, Jakob Izbicki, Nicola Gagliani. University of Hamburg Medical Institutions, Hamburg, Germany. A126 The role of macrophages and monocytes during cancer cell extravasation in 3D vascularized microfluidic models. Alexandra Boussommier-Calleja, Roger D. Kamm. Massachussetts Institute of Technology, Cambridge, MA. A127 The role of macrophages in tissue homeostasis. Ruth A. Franklin, Scott D. Pope, Ruslan Medzhitov. Yale University School of Medicine, New Haven, CT. A128 Imprime PGG, a novel, clinical-stage pathogen associated molecular pattern, modulates MDSC function, facilitating a coordinated antitumor immune response. Kathryn Fraser, Anissa Chan, Xiohong Qiu, Nadine Ottoson, Adria Bykowski Jonas, Jeremy Graff, Nandita Bose. Biothera, Eagan, MN. A129 Ablation of neuropilin 1 from glioma associated macrophages and microglia slows tumor progression. Jeremy T. Miyauchi

1, Danling Chen

1, Matthew Choi

1, Jillian Nissen

1, Kenneth Shroyer

1, David

Selwood2, Stella E. Tsirka

1.

1Stony Brook University, Stony Brook, NY;

2University College London, London, United

Kingdom. A130 The association between markers of tumor cell metabolism, the tumor microenvironment, and outcomes in patients with colorectal cancer. Stephen T. McSorley, Jennifer Clark, Hester C. van Wyk, Paul G. Horgan, Donald C. McMillan, Joanne Edwards, James H. Park. University of Glasgow, Glasgow, United Kingdom. A131 B7-H1 identifies tumor-reactive effector CD8 T cells susceptible of deletion by agonist PD-L1 antibodies. Siyu Cao, Xin Liu, Xiaosheng Wu, Aaron Mansfield, Haidong Dong. Mayo Clinic College of Medicine, Rochester, MN. A132 Multi-parametric profiling of non-small cell lung cancers reveals distinct immunophenotypes. Patrick Lizotte, Elena Ivanova, Mark Bittinger, Kwok-Kin Wong. Dana-Farber Cancer Institute, Boston, MA. A133 Micrometastatic progression of pancreas cancer: Murine model. Ankit Patel, Brian Belt, Nathania Figueroa, Sapna Patel, Aditi Murthy, Kelli Connolly, Scott Gerber, David Linehan. University of Rochester Medical Center, Rochester, NY. A134 Identification of novel Treg-specific molecule targets. Jung-Ho Kim, Jae-Seung Moon, Sang-Kyou Lee. Yonsei University, Seoul, Korea, Republic of. A135 Novel immunotherapy for intractable pancreatic cancer focusing on the myeloid derived suppressor cells in the tumor microenvironment. Takahiro Tsuchikawa, Shintaro Takeuchi, Toru Nakamura, Mizuna Takahashi, kazuho Inoko, Toshihiro Kushibiki, Koji Hontani, Masato Ono, Shota Kuwabara, Toshiaki Shichinohe, Satoshi Hirano. Gastroenterological Surgery II, Hokkaido University, Sapporo, Japan. A136 p16

INK4a status of primary tumor modulates local immune response in vulvar squamous cell

carcinoma. Jacek J. Sznurkowski, Anton Zawrocki. Medical University of Gdansk Poland, Gdansk, Poland.



A137 PD-L1 antibodies induce macrophage phenotypic and functional activation. Genevieve Hartley, William Wheat, Jonathan Coy, Steven Dow. Colorado State University, Fort Collins, CO. A138 Increased CD3(+) cell infiltration during pancreatic intraepithelial neoplasia progression in Kras

G12D/Pdx1-

Cre transgenic mouse model. Xiafei Hong, Hongmei Dai, Xianze Wang, Feng Tian, Wenming Wu, Yupei Zhao. Peking Union Medical College Hospital, BEIJING, China. A139 Antitumor effects of improved DC vaccine with ALA-PDT induced immunogenic apoptotic cells for skin squamous cell carcinoma in mice. Haiyan Zhang

1, Guolong Zhang

1, Zhixia Fan

1, Xiaojie Wang

1, Lei Shi

1, Degang

Yang1, Cody F. Bahavar

2, Feifan Zhou

2, Wei R. Chen

2, Xiuli Wang

1.

1Shanghai Skin Disease Hospital, Shanghai, China;

2Biophotonics Research Laboratory, Center for Interdisciplinary Biomedical Education and Research, University of

Central Oklahoma, Edmond, OK. A140 Check point inhibitor modulation of tumor microenvironment at orthotopic and metastatic sites using bioluminescent syngeneic cell line models in immune competent mice. Andrew McKenzie

1, Nektaria

Papadopoulou1, Simon Jiang

1, Jane Wrigley

1, Kelly Jones

1, Russell Garland

2, Neil Williams

2, Rajendra Kumari

1.

1Crown Bioscience UK, Loughborough, United Kingdom;

2KWS Biotest, Bristol, United Kingdom.

A141 Prognostic value of cancer stem cells (CSC) in head and neck squamous carcinoma (HNSCC). Michal Zabrodsky, Jan Bouček. Charles University in Prague, Prague, Czech Republic. A142 Pre-operative assessment of the tumor microenvironment of patients undergoing resection of colorectal cancer is feasible using colonoscopic biopsies. James H. Park, David Mansouri, Clare Orange, Joanne Edwards, Paul G. Horgan, Donald C. McMillan, Campbell SD Roxburgh. University of Glasgow, Glasgow, United Kingdom. A143 4-methylumbelliferone and interleukin-12 combined therapy inhibit tumor growth by inducing antitumor immunity and reducing the presence of cancer stem cells in an murine hepatocellular carcinoma model associated with fibrosis. Mariana Malvicini, Marcelo M. Rodriguez, Esteban J. Fiore, Juan Bayo, Mariana Garcia, Sofia Gomez Bustillo, Catalina Atorrasagasti, Estanislao Peixoto, Guillermo Mazzolini. Instituto de Investigaciones en Medicina Traslacional,Universidad Austral-CONICET, Derqui-Pilar, Argentina. A144 Urease-mediated alkalization of tumor microenvironment and its effects on T cell proliferation, cytokine release, and PD-1/PD-L1 interactions. Wah Yau Wong, Baomin Tian, Praveen Kumar, Kim Gaspar, Steve Demas, Sven Rohmann, Heman L. Chao. Helix BioPharma Corp., Aurora, ON, Canada. A145 The prognostic significance of programmed cell death-ligand 1 expression in pulmonary squamous cell carcinoma. Jung-Jyh Hung, Yu-Chung Wu, Wen-Hu Hsu. Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan. A146 Increase antitumor activity of immunotherapy by blocking colony stimulating factor 1 receptor and tropomyosin receptor kinase. Stephen Mok, Colm Duffy, Reginald Du, James P. Allison. MD Anderson Cancer Center, Houston, TX. A147 Differential transcriptional profiling of tumor cell populations. Sascha H. Duttke, Christopher K. Glass. UCSD, La Jolla, CA.



A148 Control of regulatory T (Treg) cell function by protein kinase C-eta (PKCη): A novel target for cancer immunotherapy. Christophe Pedros, Kok-Fai Kong, Amnon Altman. La Jolla institute for Allergy and Immunology, La Jolla, CA.

Poster Session B Monday, September 26

5:15 p.m.-7:45 p.m. Posters B001-B072, Americas Hall I/Posters B073 –B142, Americas Hall II

B001 Preliminary clinical activity and safety of an autologous AdHER2 dendritic cell vaccine in patients with advanced metastatic HER2+ solid tumors. Lauren V. Wood

1, Brenda D. Roberson

1, Piyush Agarwal

1, Andrea A.

Apolo1, David Stroncek

2, Lou M. Weiner

3, John C. Morris

4, Jason C. Steel

5, Masaki Terabe

1, MIn-Jung Lee

1, Jane

Trepel1, Sohee Shim

1, Jay A. Berzofsky

1.

1National Cancer Institute, Bethesda, MD;

2NIH Clinical Center, Bethesda,

MD; 3Georgetown Lombardi Comprehensive Cancer Center, Washington, DC;

4University of Cincinnati, Cincinnati,

OH; 5The University of Queensland, Queensland, Australia.

B002 TLR7/8-matured dendritic cells for therapeutic vaccination in AML: Results of a clinical Phase I/II trial. Katrin Deiser

1, Felix S. Lichtenegger

1, Frauke M. Schnorfeil

1, Thomas Köhnke

1, Torben Altmann

1, Veit

Bücklein1, Christian Augsberger

1, Andreas Moosmann

2, Monika Brüggemann

3, Mirjam HM Heemskerk

4, Beate

Wagner5, Wolfgang Hiddemann

1, Iris Bigalke

6, Gunnar Kvalheim

6, Marion Subklewe

1.

1Klinikum der Universität

München, LMU Munich, Munich, Germany; 2Clinical Cooperation Group Immunotherapy at the Helmholtz Zentrum

München, Munich, Germany; 3Department of Hematology, University Hospital Schleswig-Holstein, Kiel, Germany;

4Department of Hematology, Leiden University Medical Center, Leiden, Netherlands;

5Department of Transfusion

Medicine, Cellular Therapeutics and Hemostaseology, Klinikum der Universität München, LMU Munich, Munich, Germany;

6Department of Cellular Therapy, The Norwegian Radium Hospital, Oslo University Hospital, Oslo,

Norway. B003 A randomized controlled phase II clinical trial on mRNA electroporated autologous dendritic cells for stage III/IV melanoma patients who are disease-free following the local treatment of macrometastases. Bart Neyns

1, Yanina Jansen

1, Jurgen Corthals

2, Sofie Wilgenhof

1, Max Schreuer

1, Carlo Heirman

2, Kris Thielemans

2.

1University Hospital Vrije Universiteit Brussel, Brussel, Belgium;

2Vrije Universiteit Brussel, Brussel, Belgium.

B004 Peripheral blood immune profiling of anti-PD-1 therapy in human melanoma reveals a link between T cell re-invigoration and tumor burden that predicts response. Alexander Huang

1, Michael A. Postow

2, Robert J.

Orlowski1, Rosemarie Mick

1, Bertram Bengsch

1, Sasi Manne

1, Wei Xu

1, Shannon Harmon

1, Matthew Adamow

2,

Deborah Kuk2, Katherine Panangeas

2, Cristina Carerra

2, Phillip Wong

2, Felix Quagliarello

1, Kristen E. Pauken

1, Ramin

S. Herati1, Suzanne McGettigan

1, Shawn Kothari

1, Sangeeth M. George

1, Brandon Wenz

1, Kurt D'Andrea

1, Xiaowei

Xu1, Ravi K. Amaravadi

1, Giorgos Karakousis

1, Lynn M. Schuchter

1, Katherine L. Nathanson

1, Jedd D. Wolchok

2, Tara

C. Gangadhar1, John Wherry

1.


2Memorial Sloan Kettering Cancer

Center, New York City, NY B005 Cytokine production by intratumorally administered activated dendritic cells correlates with survival in a Phase I clinical trial in diverse cancers. Vivek Subbiah

1, Ravi Murthi

1, Robert Prins

2, Kyle Hendricks

3, Chitra Hosing

1,

Lori Noffsinger3, Mary McGuire

4, Robert Brown

4, Aung Naing

1, David Hong

1, Siqing Fu

1, Anthony Conley

1,

Indreshpal Kaur1, Sarah Campion

3, Marnix Bosch

5.

1MD Anderson Cancer Center, Houston, TX;

2UCLA, Los Angeles,

CA; 3Cognate Bioservices, Memphis, TN;

4UT Health, Houston, TX;

5NW BIOTHERAPEUTICS, Bethesda, MD.

B006 Large scale microarray profiling reveals four stages of immune escape in Non Hodgkin lymphomas. Jean-Jacques Fournie. Cancer Research Center of Toulouse, Toulouse, France.



B007 Improved disease-free survival in endometrial and ovarian cancer patients with low folate binding protein expression after treatment with the E39 peptide vaccine in a Phase I/IIa trial. Kaitlin M. Peace

1, Diane F.

Hale1, Timothy J. Vreeland

2, Doreen O. Jackson

1, Julia M. Greene

1, John S. Berry, IV

1, Alfred F. Trappey

1, Garth S.

Herbert1, Guy T. Clifton

1, Mark O. Hardin

3, Kathleen M. Darcy

4, Chad A. Hamilton

4, G. Larry Maxwell

4, George E.

Peoples5.

1San Antonio Military Medical Center, San Antonio, TX;

2Womack Army Medical Center, Fayetteville, NC;

3Madigan Army Medical Center, Tacoma, WA;

4Gynecologic Cancer Center of Excellence, Annandale, VA;

5Cancer

Vaccine Development Program, San Antonio, TX. B008 Imprime PGG, an intravenously administered beta glucan PAMP activates the innate immune system: A phase I clinical study to evaluate immunopharmacodynamic responses. Nadine C. Ottoson

1, Richard D. Huhn

1,

Jamie Lowe1, Ben Harrison

1, Jose Iglesias

1, Blaine Rathmann

1, Takashi Kangas

1, Lindsay R. Wurst

1, Xiaohong Qiu

1,

Anissa Chan1, Adria Bykowski Jonas

1, Kathryn Fraser

1, Richard M. Walsh

1, Katie Ertelt

1, Steven M. Leonardo

1, Ross

Fulton1, Keith Gorden

1, Mark A. Matson

2, Mark Uhlik

1, Jeremy Graff

1, Nandita Bose

1.

1Biothera Pharmaceuticals,

Inc, Eagan, MN; 2Prism Clinical Research, Minneapolis, MN.

B009 Phase I clinical trial of a PSA, IL-2, GM-CSF containing prostate cancer vaccine in PSA defined biochemical recurrent prostate cancer patients. Jonathan F. Head

1, Gregory A. Daniels

2, Michelle McKinney

2, Weg Ongkeko

3,

Kyoko Sakamoto3, Jessica Wang-Rodriguez

4.

1Oncbiomune Pharmaceuticals, Baton Rouge, LA;

2Moores Cancer

Center, University of California San Diego, La Jolla, CA; 3Department of Surgery, University of California San Diego,

La Jolla, CA; 4Department of Pathology, University of California San Diego, La Jolla, CA.

B010 Antitumor activity and immune correlates of PEGylated human IL-10 (AM0010) alone or in combination with anti-PD-1. Aung Naing

1, Jeffrey R. Infante

2, Kyriakos P. Papadopoulos

3, Deborah J. Wong

4, Karen A. Autio

5,

Gerald S. Falchook6, Manish Patel

7, Shubham Pant

8, Amita Patnaik

3, Melinda Whiteside

9, Johanna C. Bendell

2, John

Mumm9, Ivan H. Chan

9, Gail L. Brown

9, Peter VanVlasselaer

9, J. R. Hecht

4, David S. Hong

1, Nizar M. Tannir

1, Martin

Oft9.


2Sarah Cannon Research Institute / Tennessee Oncology, PLLC;,

Nashville, TN; 3START Center for Cancer Care, San Antonio, TX;

4University of California Los Angeles (UCLA), Los

Angeles, CA; 5Memorial Sloan-Kettering Cancer Center, New York, NY;

6Sarah Cannon Research Institute at

HealthONE, Denver, CO; 7Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL;

8MD Anderson

Cancer Center, Houston, CA; 9ARMO, Palo Alto, CA.

B011 Human IL-2 mutant exhibits a higher antitumor efficacy and lower toxicity than wildtype IL-2 in different preclinical contexts. Tania Carmenate

1, Magela Montalvo

1, Gertrudis Rojas

1, Dasha Fuentes

2, Kalet Leon

1.

1Center

of Molecular Immunology, Habana, Cuba; 2Centro Nacional para Animales de Laboratorio, Habana, Cuba.

B012 Preclinical study of Kiatomab, a novel monoclonal antibody to the cancer stem cell surface marker KIAA1114, for anti-cancer therapy in colorectal carcinoma. Young Min Kim

1, Sae Won Kim

1, Seungwon Lee

2,

Hyekang Kim2, Ji-Hae Kim

1, Han Wook Park

2, Young Chul Sung

1, Seung-Woo Lee

1.

1POSTECH, Pohang, Korea,

Republic of; 2Pohang University of Science and Technology, Pohang, Korea, Republic of.

B013 Targeting FSTL1 augments therapeutic activities of immune checkpoint inhibitors. Chie Kudo-Saito, Yamato Ogiwara, Marina Hennmi, Kazunori Aoki. National Cancer Center, Tokyo, Japan. B014 Improved therapeutic activity of agonistic, human anti-CD40 monoclonal Abs by selective Fc Receptor-engagement. Rony Dahan, Jeffrey V. Ravetch. The Rockefeller University, New York, NY.



B015 Expansion and activation of CD103

+ dendritic cell progenitors at the tumor site transform tumor response

to PD-L1 and BRAF inhibition. Hélène Salmon1, Juliana Idoyaga

2, Adeeb Rahman

1, Romain Remark

1, Sacha Gnjatic

1,

Nina Bhardwaj1, Joshua Brody

1, Anna Karolina Palucka

3, Florent Ginhoux

4, Miriam Merad

1.

1Icahn School of

Medicine at Mount Sinai, New York, NY; 2Stanford University School of Medicine, Stanford, CA;

3The Jackson

Laboratory for Genomic Medicine, Farmington, CT; 4Singapore Immunology Network, Agency for Science,

Technology and Research, Singapore, Singapore. B016 Costimulatory T-cell engagement by PRS-343, a CD137 (4-1BB)/HER2 bispecific, leads to tumor growth inhibition and TIL expansion in humanized mouse model. Marlon J. Hinner

1, Rachida-Siham Bel Aiba

1, Corinna

Schlosser1, Thomas Jaquin

1, Andrea Allersdorfer

1, Sven Berger

1, Alexander Wiedenmann

1, Gabriele Matschiner

1,

Julia Schüler2, Ulrich Moebius

1, Christine Rothe

1, Shane A. Olwill

1.

1Pieris Pharmaceuticals, Inc., Boston, Germany;

2Oncotest GmbH, Freiburg, Germany.

B017 Bacterial minicells decrease tumor development and modulate immunity in a mouse mouse model of colon cancer. Mengxi Tian

1, Mohammad W. Khan

1, Shea Grenier

1, Shingo Tsuji

2, Matthew A. Giacalone

2, Kathleen

L. McGuire1.

1San Diego State University, San Diego, CA;

2Vaxiion Therapeutics, San Diego, CA.

B018 A novel IDO1 inhibitor combined with targeted immunotherapy durably increases survival in a mouse model of glioblastoma. Erik Ladomersky, Lijie Zhai, Galina Gritsina, Kristen L. Lauing, Matthew Genet, C. David James, Derek A. Wainwright. Northwestern University Feinberg School of Medicine, Chicago, IL. B019 LAG3 is an immunotherapeutic target in murine triple negative breast cancers whose activity is significantly enhanced in combination with phosphatidylserine targeting antibodies. Michael J. Gray, Jian Gong, Jeff Hutchins, Bruce Freimark. Peregrine Pharmaceuticals, Tustin, CA. B020 STING activation in the tumor microenvironment using a synthetic human STING-activating cyclic dinucleotide induces potent antitumor immunity. Sarah M. McWhirter

1, Laura Hix Glickman

1, Tony Desbien

1,

Kelsey Sivick Gauthier1, David Kanne

1, Shailaja Kasibhatla

2, Jie Li

2, AnneMarie Culazzo Pferdekamper

2, George

Katibah1, Ed Lemmens

1, Leticia Corrales

1, Meredith Leong

1, Chudi Ndubaku

1, Justin Leong

1, Leonard Sung

1, Lianxing

Zheng3, Charles Cho

2, Yan Feng

3, Jeffery M. McKenna

3, John A. Tallarico

3, Steven L. Bender

2, Thomas W. Dubensky,

Jr.1.

1Aduro Biotech, Berkeley, CA;

2Genomics Institute of the Novartis Research Foundation, San Diego, CA;

3Novartis Institutes for BioMedical Research, Cambridge, MA.

B021 Single domain antibodies targeting CTLA-4 demonstrate a critical role for Fc in the antitumor response. Michael Dougan

1, Jessica Ingram

1, Olga Blomberg

1, Mohammad Rashidian

1, Edmund Keliher

2, Ralph

Weissleder2, Steven Almo

3, Hidde Ploegh

1.

1MIT Whitehead Institute for Biomed. Research, Cambridge, MA;

2Massachusetts General Hospital, Boston, MA;

3Albert Einstein College of Medicine, New York, NY.

B022 Intratumoral CD40 activation and checkpoint blockade induces systemic anti-melanoma immunity that eradicates disseminated tumors. Manisha Singh, Christina Vianden, Adi Diab, Patrick Hwu, Willem W. Overwijk. MD Anderson Cancer Center, Houston, TX.



B023 Antibody blockade of Semaphorin 4D enhances infiltration of APC and CD8 T cells and reduces immune suppression to facilitate immune-mediated tumor rejection. Elizabeth E. Evans

1, Holm Bussler

1, Crystal Mallow

1,

Christine Reilly1, Sebold Torno

1, Ekaterina Klimatcheva

1, Maria Scrivens

1, Cathie Foster

1, Alan Howell

1, Leslie Balch

1,

Alyssa Knapp1, John E. Leonard

1, Mark J. Paris

1, Terrence L. Fisher

1, Siwen Hu-Lieskovan

2, Antoni Ribas

2, Ernest S.

Smith1, Maurice Zauderer

1.

1Vaccinex, Rochester, NY;

2David Geffen School of Medicine at UCLA, Los Angeles, CA.

B024 First-in-class antibody targeting soluble NKG2D ligand sMIC to enhance checkpoint cancer immunotherapy. Jennifer D. Wu, Jinyu Zhang, Fahmin Basher, Mark Rubinstein. Medical University of South Carolina, Charleston, SC. B025 p53 responsive endogeneous retrovirus as early mediators of immunosurveillance. Kojiro Tashiro, Robyn Leary, Anindya Bagchi. University of Minnesota, Minneapolis, MN. B026 MDSCs and CD8 effector memory T cells correlate with survival in melanoma patients treated with ipilimumab. Yago Pico De Coaña

1, Maria Wolodarski

1, Isabel Poschke

2, Yuya Yoshimoto

3, Giuseppe Masucci

1, Johan

Hansson1, Rolf Kiessling

1.

1Karolinska Institutet, Stockholm, Sweden;

2German Cancer Research Center, Heidelberg,

Germany; 3Gunma University Graduate School of Medicine, Gunma, Japan.

B027 BGB324, a selective small molecule inhibitor of AXL receptor tyrosine kinase, enhances immune checkpoint inhibitor efficacy. Katarzyna Wnuk-Lipinska

1, Kjersti Davidsen

2, Magnus Blø

1, Linn Hodneland

1, Agnete

Engelsen2, Jing Kang

2, Maria Lie

2, Sebastien Bougnaud

2, Kristina Aguilera

1, Lavina Ahmed

1, Agata Rybicka

1, Elina

Milde1, Paulina Deyna

1, Anna Boniecka

1, Oddbjørn Straume

2, Salem Chouaib

3, Rolf Brekken

4, Gro Gausdal

1, James

Lorens2.

1BerGenBio AS, Bergen, Norway;

2University of Bergen, Bergen, Norway;

3Institut Gustave Roussy, Paris,

France; 4UT Southwestern Medical Center, Dallas, TX.

B028 Blockade of the CD47 “Do not eat” signal by TTI-621 (SIRPαFc) leads to enhanced antitumor CD8

+ T cell

responses in vitro. Natasja Nielsen Viller, Tran Truong, Emma Linderoth, Lisa D. Johnson, Stephane Viau, Gloria H. Y. Lin, Mark Wong, Xinli Pang, Penka S. Petrova, Robert A. Uger. Trillium Therapeutics Inc., Mississauga, ON, Canada. B029 OMX: An oxygen carrier biotherapeutic that ameliorates the hypoxic tumor microenvironment and promotes anticancer T cell activity. Kevin G. Leong, Natacha Le Moan, Yuqiong Pan, Philberta Leung, Catherine Bedard, Jon Winger, Stephen PL Cary, Ana Krtolica. Omniox Inc, San Carlos, CA. B030 Development and validation of a phenotypic screening platform for the identification of novel immuno-oncology targets. Virginie Rabolli, Murielle Martini, Ariane Scoumanne, Marie-Claire Letellier, Stefano Crosignani, Christophe Quéva, Michel Detheux, Jakub M. Swiercz, Sandra Cauwenberghs. iTeos Therapeutics, Gosselies, Belgium. B031 FAK/PYK2 inhibition enhances antitumor efficacy of anti-PD-1 and anti-4-1BB antibodies. Jonathan A. Pachter, David T. Weaver. Verastem, Inc., Needham, MA.



B032 The PI3K-γ inhibitor, IPI-549, increases antitumor immunity by targeting tumor-associated myeloid cells and remodeling the immune-suppressive tumor microenvironment. Matthew Rausch

1, Jeremy Tchaicha

1, Thomas

Tibbitts1, Olivier De Henau

2, Sujata Sharma

1, Melissa Pink

1, Joseph Gladstone

1, Jennifer Proctor

1, Mark Douglas

1,

Howard Stern1, Taha Merghoub

2, Jedd Wolchok

2, Karen McGovern

1, Jeff Kutok

1, David Winkler

1.

1Infinity

Pharmaceuticals, Inc, Cambridge, MA; 2Memorial Sloan Kettering Cancer Center, New York, NY.

B033 A novel IL-2 and IL-15 antagonist shifting the immune balance towards tolerance: Potential therapeutic applications. Meghnem Dihia, Sebastien Morisseau, Kilian Trillet, Marie Frutoso, Isabelle Barbieux, Agnes Quemener, Yannick Jacques, Erwan Mortier. INSERM UMR892, Nantes, France. B034 Smac mimetics synergistically improve the efficacy of cancer immunotherapies including immune checkpoint blockade in preclinical models. Eric LaCasse, Shawn Beug, Cristin Healey, Caroline Beauregard, Tarun Sanda, Tommy Alain, Robert Korneluk. Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada. B035 CXCL8/CXCR1 signaling promotes angiogenesis and hematopoietic stem and progenitor cell function. Bradley W. Blaser

1, Jessica L. Moore

1, Elliott Hagedorn

1, Brian Li

1, Vera Binder

2, Owen Tamplin

3, Leonard

I. Zon1.

1Boston Children's Hospital, Boston, MA;

2Dr. von Hauner Children's Hospital, Ludwig-Maximillian's

University, Munich, Germany; 3University of Illinois College of Medicine, Chicago, IL.

B036 Neo-antigen landscape dynamics during human melanoma-T cell interactions. Els M.E. Verdegaal

1, Noel

de Miranda1, Marten Visser

1, Tom Harryvan

1, Marit van Buuren

2, Rikke Andersen

3, Sine Hadrup

3, Caroline van der

Minne1, Remko Schotte

4, Hergen Spits

4, John Haanen

2, Ellen Kapiteijn

1, Ton Schumacher

2, Sjoerd H. Van Der Burg

1.

1Leiden University Medical Center, Leiden, Netherlands;


3University Hospital Herlev, Copenhagen, Denmark;

4AIMM Therapeutics, Amsterdam, Netherlands.

B037 Macrophage repolarization therapy in metastatic colorectal cancer: CCR5 inhibition. Niels Halama

1, Inka

Zoernig1, Anna Berthel

1, Christoph Kahlert

2, Fee Klupp

3, Meggy Suarez-Carmona

1, Juergen Krauss

1, Karsten Brand

4,

Felix Lasitschka5, Tina Lerchl

1, Claudia Luckner-Minden

1, Alexis Ulrich

6, Juergen Weitz

2, Martin Schneider

7, Markus

W. Buechler7, Laurence Zitvogel

8, Thomas Herrmann

9, Axel Benner

10, Christina Kunz

10, Stephan Luecke

10, Christoph

Springfeld1, Christine Falk

11, Dirk Jaeger

1.

1National Center for Tumor Diseases, Heidelberg, Germany;

2University

Hospital Dresden, Dresden, Germany; 3University Hospital Heidelberg, Heidelberg, Germany;

4Institute for

Pathology, University Hospital, Heidelberg, Germany; 5Institute of Pathology, University Hospital Heidelberg,

Heidelberg, Germany; 6University Hospital, Department of Surgery, Heidelberg, Germany;

7University Hospital

Heidelberg, Department of Surgery, Heidelberg, Germany; 8Institute Gustave Roussy, Paris, France;

9Klinikum

Heide, Heide, Germany; 10

German Cancer Research Center, Heidelberg, Germany; 11

Medical School Hannover, Hannover, Germany. B038 Class IIa HDAC inhibition promotes an antitumor macrophage phenotype that induces breast tumor regression and inhibits metastasis. Jennifer L. Guerriero, Alaba Sotayo, Holly Ponichtera, Alexandra Pourzia, Sara Schad, Ruben Carrasco, Suzan Lazo, Roderick Bronson, Anthony Letai. Dana-Farber Cancer Institute, Boston, MA. B039 Small-molecule inhibitors of CD73 promote activation of human CD8+ T cells and have profound effects on tumor growth and immune parameters in experimental tumors. Juan C. Jaen, Jay P. Powers, Ada Chen, Manmohan R. Leleti, Jarek Kalisiak, Ulrike Schindler, Joanne Bl Tan, Steve Young, Shin-Heng Chiou, Laurent Debien. Arcus Biosciences, Inc., Hayward, CA.



B040 Imiquimod initiates tumor specific overload of the ER stress response in Tasmanian devil facial cancer cells. Amanda L. Patchett

1, Terry L. Pinfold

1, Cesar Tovar

1, Bruce Lyons

2, Gregory M. Woods

1.

1Menzies Institute for

Medical Research, University of Tasmania, Hobart, Australia; 2School of Medicine, University of Tasmania, Hobart,

Australia. B041 Ibrutinib treatment counteracts the immunosuppressive activity of malignant B cells. Meixiao Long, Kyle A. Beckwith, Priscilla Do, Amber Gordon, Amy Lehman, Kami Maddocks, Carolyn Cheney, Jeffrey Jones, Leslie Andritsos, Farrukh Awan, Jennifer Woyach, Johnson J. Amy, Natarajan Muthusamy, John Byrd. The Ohio State University, Columbus, OH. B042 Potent and selective small molecule USP7 inhibitors for cancer immunotherapy. Suresh Kumar

1, Jian Wu

1,

Liqing Wang2, Jack Wang

1, Ivan Sokirniy

1, Hui Wang

1, Glen Fegley

1, Joseph Weinstock

1, Michael Mattern

1, Wayne

W. Hancock2.

1Progenra Inc, Malvern, PA;

2Children's Hospital of Philadelphia, Philadelphia, PA.

B043 Systems pharmacology modeling of anti-CD20/CD3 T-cell dependent bispecific antibody and its application to clinical trial design. Iraj Hosseini, Kapil Gadkar, Eric Stefanich, Chi-Chung Li, Laura Sun, Yu-Waye Chu, Saroja Ramanujan. Genentech Inc., San Francisco, CA. B044 Patient-specific immunotherapy through TCR gene transfer. Lorenzo F. Fanchi

1, Laura Bies

2, Ji-Ying Song

1,

Carsten Linnemann2, Ton Schumacher

1.


2Kite Pharma,

Amsterdam, Netherlands. B045 Arginase inhibitor CB-1158 elicits immune-mediated antitumor responses as a single agent and in combination with other immunotherapies. Susanne M. Steggerda, Mark Bennett, Jason Chen, Ethan Emberley, Matthew Gross, Tony Huang, Weiqun Li, Andy MacKinnon, Amani Makkouk, Gisele Marguier, Silinda Neou, Alison Pan, Tracy Wang, Melissa Works, Jing Zhang, Winter Zhang, Francesco Parlati. Calithera Biosciences, South San Francisco, CA. B046 Therapeutic mechanisms of anti-4-1BB antibodies in cancer: agonism versus regulatory T cell depletion. Marcus Remer, Anne Rogel, Sarah Buchan, Peter W.M. Johnson, Aymen Al-Shamkhani. University of Southampton, Southampton, United Kingdom. B047 Combining natural killer T cell immunotherapy with chemotherapy induced immunogenic cell death to target post-surgical breast cancer metastasis. Simon Gebremeskel

1, Kaitlyn Tanner

2, Lynnea Lobert

2, Brent

Johnston2.

1Beatrice Hunter Cancer Research Institute, Halifax, NS, Canada;

2Dalhousie University, Halifax, NS,

Canada. B048 A novel PI3K delta inhibitor suppresses tumor progression by immune modulation. ZuSheng Xu

1,

Yangtong Lou1, Jie Tan

2, Chong Wang

2, Xiaomei Ge

2, Ying Gu

2, He Zhou

2.

1Shanghai Yingli Pharmaceuticals Co. Ltd,

Shanghai, China; 2Shanghai ChemPartner Co. Ltd, Shanghai, China.

B049 Immunotherapy of EBV associated gastric cancer using EBV specific T cells. Jae Seung Moon, Jung Ho Kim, Sang Kyou Lee. Yonsei University, Seoul, Korea, Republic of.



B050 Functional characterization of virus specific stem cell like memory T cells, their maturation in vitro, and potential contribution to secondary T cell responses. Tzu-yun Kuo

1, Aisha N. Hasan

2, Richard J. O'Reilly

2.

1Weill

Cornell Medical College, New York, NY; 2 Cancer Center, New York, NY.

B051 Super cross-presentation of tumor antigens by synthetic design of an anti-phosphatidylserine bridge protein. Daniel Corey

1, Aaron Ring

2, Melissa McCracken

1, Masanori Miyanishi

1, Sydney Gordon

1, Irving Weissman

1.

1Stanford University, Institute for Stem Cell Biology and Regenerative, CA;

2Yale University, Department of

Immunobiology, CT.

B052 Peroxisome proliferator-activated receptor delta agonist GW501516 enhances the efficacy of adoptive cell therapy. Samuel Saibil, Michael St. Paul, Pamela Ohahsi. Princess Margaret Cancer Centre, Toronto, ON, Canada.

B053 Characterizing the effects of the DNA methylation inhibitor 5-AZA-CdR during CD8 T cell expansion. Helen Loo Yau. University of Toronto, Toronto, ON, Canada. B054 Evaluation of NY-BR-1 as a suitable antigen for CAR based immunotherapy. Patrick Schmidt

1, Claudia

Luckner Minden1, Claudia Ziegelmeier

1, Isabella Gosch

1, Niels Halama

1, Frank Momburg

2, Rosa Eurich

2, Sarah

Schott3, Frederik Marmé

3, Andreas Schneeweiß

3, Claus Peter Heußel

4, Dirk Jäger

1, Inka Zörnig

1.

1Department of

Medical Oncology, National Center for Tumor Diseases, Heidelberg, Germany; 2C c C p U “App d

Tu I u y”, G C c R s ch C (D FZ), H d b , G y; 3Department of Obstetrics and

Gynecology, National Center for Tumor Diseases, Heidelberg, Germany; 4Department of Diagnostic and

Interventional Radiology with Nuclear Medicine, Thoraxklinik and Heidelberg University Hospital, Heidelberg, Germany, Heidelberg, Germany. B055 Augmentation of OX40-dependent NK mediated antitumor activity is dependent on antibody cross-linking. Sean H. Lim

1, Anna H. Turaj

1, Jane Willoughby

1, Claude H.T. Chan

1, Christine A. Penfold

1, Peter W.M.

Johnson1, Martin J. Glennie

1, Mark S. Cragg

1, Ronald Levy

2.

1University of Southampton, Southampton, United

Kingdom; 2Stanford University, Stanford, CA.

B056 Harnessing tissue resident memory T cells to combat solid tumors. Pamela C. Rosato, Luke S. Manlove, Christine E. Nelson, Christopher A. Pennell, Vaiva Vezys, David Masopust. University of Minnesota, Minneapolis, MN. B057 The CD122-biased immunostimulatory cytokine NKTR-214 combined with checkpoint blockade leads to mobilization of antitumor immunity and synergistic activity. John L. Langowski, Murali Addepalli, Laurie VanderVeen, Rhoneil Pena, Ravikumar Nutakki, Yolanda Kirksey, Ute Hoch, Jonathan Zalevsky, Stephen K. Doberstein, Deborah H. Charych. Nektar Therapeutics, San Francisco, CA. B058 Development of AVID200, a novel and highly potent TGF-beta neutralizing immunotherapy. Maureen D. O'Connor-McCourt

1, Anne E.G. Lenferink

2, John Zwaagstra

2, Traian Sulea

2, Jason Baardsnes

2, Catherine Collins

2,

Christiane Cantin2, Lucie Couture

2, Limei Tao

2, Yves Durocher

2, Renu Singh

2, James Koropatnick

3.

1Formation

Biologics, Montreal, QC, Canada; 2National Research Council of Canada, Montreal, QC, Canada;

3Lawson Health

Research Institute, London, ON, Canada.



B059 Local intratumoral treatment with low-dose CD40 and TLR4 agonists overcomes resistance to PD-1 blockade to regress tumors systemically. Danny N. Khalil, Luis Felipe Campesato, Yanyun Li, Taha Merghoub, Jedd D. Wolchok. Memorial Sloan Kettering Cancer Center, New York, NY. B060 Small molecule inhibitors of the anti-inflammatory TAM receptor MerTK. Sacha J. Holland, Alexander M. Owyang, Sylvia Braselmann, Chrystelle Lamagna, Sothy Yi, Chi Young, Roy Frances, Arthur Bagos, Meagan Chan, Ernest Tai, Stacey Siu, Gary Park, David Lau, Matt Duan, Rao Kolluri, Jiaxin Yu, Ihab Darwish, Somasekhar Bhamidipati, Donald G. Payan, Esteban Masuda. Rigel Pharmaceuticals, Inc., S. San Francisco, CA. B061 CD81: A new target for therapy of B cell lymphoma. Felipe Vences-Catalán, Chiung-Chi Kuo, Ranjani Rajapaksa, Ronald Levy, Shoshana Levy. Stanford University, Stanford, CA. B062 Immune activation by LMP1 CD40 pathway and LMP1-IPS-1 STING pathway activators. Richard S. Kornbluth

1, Sachin Gupta

2, James M. Termini

2, Elizabeth Guirado

2, Geoffrey W. Stone

2.

1Receptome, LLC, La Jolla,

CA; 2Miller School of Medicine, University of Miami, Miami, FL.

B063 Oncolytic adenoviruses armed with tumor necrosis factor alpha and interleukin-2 enable successful adoptive T cell therapy of solid tumors. Mikko Siurala

1, Riikka Havunen

2, João Santos

1, Siri Tähtinen

2, Dipongkor

Saha2, Markus Vähä-Koskela

2, Michael Behr

3, Dirk M. Nettelbeck

3, Anja Ehrhardt

4, Suvi Parviainen

1, Akseli

Hemminki1.

1TILT Biotherapeutics Ltd, Helsinki, Finland;

2Cancer Gene Therapy Group, Faculty of Medicine,

University of Helsinki, Helsinki, Finland; 3German Cancer Research Center (DKFZ), Heidelberg, Germany;

4Witten/Herdecke University, Witten, Germany.

B064 Induction of protective antitumor immunity through attenuation of endoplasmic reticulum aminopeptidase 1 function. Gessa Sugiyarto, Ian Bailey, Tim Elliott, Edward James. University of Southampton, Southampton, United Kingdom. B065 Use of simultaneous detection of externalized CD107a and CD137 for evaluation of specificity and effector functions of polyclonal T-cells produced for adoptive cellular immunotherapy of prostate cancer. Pavla Taborska, Dmitry Stakheev, Katerina Vavrova, Petra Vrabcova, Jirina Bartunkova, Daniel Smrz. 2nd Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Republic. B066 The hexavalent CD40 agonist APG1233 is a superior inducer of immune cell activation compared to trimeric formats or agonistic anti-CD40 antibodies. Christian Merz, Jaromir Sykora, Meinolf Thiemann, David M. Richards, Thamara Beyer, Stefanie Kühn, Harald Fricke, Christian Gieffers, Oliver Hill. Apogenix AG, Heidelberg, Germany. B067 Preclinical data of novel enantiomeric oligonucleotides for cancer immunotherapy: The TLR9 agonist EnanDIM. Kerstin Kapp

1, Barbara Volz

1, Detlef Oswald

1, Burghardt Wittig

2, Manuel Schmidt

1.

1MOLOGEN AG,

Berlin, Germany; 2Foundation Institute Molecular Biology and Bioinformatics, Freie Universitaet Berlin, Berlin,

Germany. B068 Hydrocortisone, prednisolone, methylprednisolone, and dexamethasone inhibit CetuGEX™-mediated ADCC in vitro. Christoph Goletz, Johanna Rühmann, Beate Habel, Antje Danielczyk, Steffen Goletz. Glycotope, Berlin, Germany.



B069 The best is not enough—when it is alone: Current clinical doses of humanized anti-Her2 antibodies should be applied in combination to delay development of trastuzumab resistance by additively enhancing ADCC. Gábor Tóth

1, Á pád zöő

1, László Simon

1, Yosef Yarden

2, Já s zö ős

1, György Vereb

1.

1University of

Debrecen, Debrecen, Hungary; 2Weizmann Institute of Science, Rehovot, Israel.

B070 IPI-549-01: A Phase I/Ib first in human study of IPI-549, a PI3K-γ inhibitor, as monotherapy and in combination with pembrolizumab in subjects with advanced solid tumors. Anthony Tolcher

1, David Hong

2, Ryan

Sullivan3, James Mier

4, Geoffrey Shapiro

5, Joseph Pearlberg

6, Les Brail

6, Jahnavi Kharidia

6, Lixin Han

6, Claudio

Dansky Ullmann6, Howard M. Stern

6, Jedd D. Wolchok

7.

1South Texas Accelerated Research Therapeutics (START),

San Antonio, TX; 2MD Anderson Cancer Center, Houston, TX;

3Massachusetts General Hospital, Boston, MA;

4Beth

Israel Deaconess Medical Center, Boston, MA; 5Dana-Farber Cancer Institute, Boston, MA;

6Infinity

Pharmaceuticals, Inc., Cambridge, MA; 7Memorial Sloan Kettering Cancer Center, New York, NY.

B072 Phase Ib trial of the RNActive cancer vaccine BI 1361849 (CV9202) and local radiotherapy in patients with stage IV non-small cell lung cancer (NSCLC) with disease control after first-line chemotherapy or during therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: Updated clinical results and immune responses. M. M. Hipp

1, M. Sebastian

2, C. Weiss

3, M. Früh

4, M. Pless

5, R. Cathomas

6, W. Hilbe

7, G. Pall

7, T. Wehler

8,

J. Alt8, H. Bischoff

9, M. Geißler

10, F. Griesinger

11, J. Kollmeier

12, A. Papachristofilou

13, F. Doener

1, M. Fotin-Mleczek

1,

H. S. Hong1, K. J. Kallen

1, U. Klinkhardt

14, S. D. Koch

1, E. Niehus

14, B. Scheel

1, A. Schröder

14, T. Seibel

14, U. Gnad-

Vogt14

, A. Zippelius15

. 1CureVac AG, Tübingen, Germany;

2Department of Hematology/Oncology, J.W. Goethe

University Hospital Frankfurt, Frankfurt, Germany; 3Centre of Radiology, University Hospital Frankfurt, Frankfurt,

Germany; 4Department of Oncology and Hematology, Cantonal Hospital of St Gallen, St Gallen, Switzerland;

5Department of Medical Oncology, Cantonal Hospital of Winterthur, Winterthur, Switzerland;

6Department of

Internal Medicine, Cantonal Hospital Graubünden, Chur, Switzerland; 7Department of Internal Medicine V

(Haematology and Oncology), University Hospital Innsbruck, Innsbruck, Austria; 8Third Department of Internal

Medicine, Johannes Gutenberg-University Hospital Mainz, Mainz, Germany; 9Department of Internal

Medicine/Oncology, Thoraxklinik- Heidelberg GmbH, Heidelberg, Germany; 10

Department of Oncology and Gastroenterlogy, Klinikum Esslingen GmbH, Esslingen, Germany;

11Department of Hematology and Oncology, Pius

Hospital, Oldenburg, Germany; 12

Department of Pneumology, Heckeshorn Lung Clinic, Berlin, Germany; 13

Department of Radio-Oncology, University Hospital Basel, Basel, Switzerland; 14

CureVac AG, Frankfurt, Germany; 15

Department of Oncology, University Hospital Basel, Basel, Germany. B073 Protein nanoparticles for controllable T cell activation. Marc J. Lajoie, Gabriel Butterfield, Elizabeth Gray, Kate DaPron, Daniel Stetson, David Baker, Neil King. University of Washington, Seattle, WA. B074 Automatic identification of cell niches and immune interactions important for clinical outcomes using multiparameter imaging and deep neural networks. Salil S. Bhate, Nikolay Samusik, Yury Goltsev, Garry P. Nolan. Stanford University, Stanford, CA. B075 Conversion of extracellular signals to programmable genome manipulation via CRISPRouter. P C Dave P. Dingal, Nathan Kipniss, Yuchen Gao, Lei S. Qi. Stanford University, Stanford, CA. B076 PIN-2: A novel immunopriming peptide with immunomodulatory activity linking the innate and adaptive immune systems. Joshua B. Goldberg, Sophie Hanscom, Colin B. Bier. PIN Pharma, Inc., New York, NY.



B077 Non-invasive imaging of the PD-1/PD-L1 pathway in syngeneic murine tumor models. Sandra Heskamp, Janneke D.M. Molkenboer-Kuenen, Erik H. Aarntzen, Otto C. Boerman. Radboud university medical center, Nijmegen, Netherlands. B078 GoTCR: Inducible MyD88/CD40 (iMC) enhances proliferation and survival of tumor-specific TCR-modified T cells and improves antitumor efficacy in myeloma. Tsvetelina Pentcheva-Hoang

1, David Torres

1, Tania

Rodriguez1, Ana Korngold

1, An Lu

1, Jeannette Crisostomo

1, Annemarie Moseley

1, Lorenz Jahn

2, Mirjam H.M.

Heemskerk2, Kevin Slawin

1, David Spencer

1, Aaron Foster

1.

1Bellicum Pharmaceuticals, Houston, TX;

2Leiden

University Medical Center, Leiden, Netherlands. B079 The efficacy of CD133 BiTEs and CAR-T cells in preclinical model of recurrent glioblastoma. Parvez Vora

1,

Chirayu Chokshi1, Maleeha Qazi

1, Chitra Venugopal

1, Sujeivan Mahendram

1, Mohini Singh

1, Jarrett Adams

2, David

Bakhshinyan1, Max London

2, Minomi Subapanditha

1, Nicole McFarlane

1, James Pan

2, Jonathan Bramson

1, Jason

Moffat2, Sachdev Sidhu

2, Sheila Singh

1.

1McMaster University, Hamilton, ON, Canada;

2University of Toronto,

Toronto, ON, Canada. B080 Noninvasive imaging of antitumor responses as a possible predictive tool. Mohammad Rashidian, Hidde Ploegh. Whitehead Institute/MIT, Cambridge, MA. B081 Spatially-resolved, multiplexed (up to 800 plex) digital characterization of protein and mRNA abundance in FFPE tissue sections: Application to immuno-oncology. Dwayne Dunaway, Jaemyeong Jung, Chris Merritt, Isaac Sprague, Philippa Webster, Sarah Warren, Joseph Beechem. NanoString Technologies, Seattle, WA. B082 Migratory T cells demonstrate superior persistence and enhanced tumor control. Gabrielle Romain

1,

Harjeet Singh2, Ivan Liadi

1, Jay R Adolacion

1, Laurence J.N. Cooper

3, Navin Varadarajan

1.

1University of Houston,

Houston, TX; 2University of Texas M.D. Anderson Cancer Center, Houston, TX;

3Ziopharm Oncology, Boston, MA.

B083 Novel mRNA manufacturing techniques using modification of nucleosides and purification improves the efficacy of mRNA chimeric antigen receptor T cells. Jessica Foster, Namrata Choudhari, David Barrett, Adam Resnick. The Children's Hospital of Philadelphia, Philadelphia, PA. B084 Transparent tumor tomography (T3): Spatial analysis for PD-L1 checkpoint blockade immunotherapy. Steve Seung-Young Lee. The University of Chicago, Chicago, IL. B085 Combining transcriptomic profiling and genome engineering to dissect regulation of tumor immunology. Le Cong, Meromit Singer, Chao Wang, John Kwon, Ana Anderson, Orit Rozenblatt-Rosen, Vijay Kuchroo, Aviv Regev. Broad Institute, Cambridge, MA. B086 CRISPR-Cas9 engineering and screening in primary human T cells. Cristina Ghirelli, Thibault Laurent, Kim Hoenderdos, Chris Lowe, Nicola McCarthy, Jonathan Moore. Horizon Discovery, Cambridge, United Kingdom. B087 Revealing antibody repertoires and RAG tracking by linear amplification mediated-high-throughput genome-wide translocation sequencing. Jiazhi Hu, Sherry G. Lin, Zhaoqing Ba, Zhou Du, Yu Zhang, Frederick W. Alt. Boston Children's Hospital, Boston, MA.



B088 Generation of immuno-modulatory receptor binding bispecific antibodies to modulate tumor immunity. Rinse Klooster, Cecile Geuijen, Mark Throsby. Merus NV, Utrecht, Netherlands. B089 High-throughput profiling of HLA allele-specific peptides by MS for improved epitope prediction. Michael S. Rooney

1, Jennifer G. Abelin

1, Derin B. Keskin

2, Siranush Sarkizova

3, Christina Hartigan

4, Wandi Zhang

5, John

Sidney6, Jonathan Stevens

7, William J. Lane

8, Guang L. Zhang

9, Karl R. Clauser

4, Nir Hacohen

10, Steven A. Carr

4,

Catherine J. Wu2.

1Neon Therapeutics, Cambridge, MA;

2Dana-Farber Cancer Institute, Boston, MA;

3Harvard

Medical School, Boston, MA; 4Broad Institute of MIT and Harvard, Cambridge, MA;

5Dana-Farber Cancer Institute,,

Boston, MA; 6La Jolla Institute for Allergy and Immunology, La Jolla, CA;

7Brigham and Women's Hospital, Boston,

MA; 8B h d W ’s H sp , B s , A;

9Boston University, Boston, MA;

10Center for Cancer

Immunology at Massachusetts General Hospital, Cambridge, MA. B090 Evaluation of a novel impedance-based assay for label free and dynamic assessment of CAR-T constructs efficacy against B-cell leukemia and lymphoma. Chelsea Xue

1, Fabio Cerignoli

2, Vladimir Senyukov

3, Piotr Pierog

1,

Thomas Miller3, Amy Shaw

1, Biao Xi

2, Lincoln Muir

2, Yama Abassi

2, Sadik Kassim

1.

1Novartis, Cambridge, MA;

2ACEA

Biosciences, San Diego, CA; 3Novartis, Morris Plain, NJ.

B091 A LAG-3/PD-L1 bispecific antibody inhibits tumor growth in two syngeneic colon carcinoma models. Jacqueline Doody, Matthew Kraman, Katy Everett, Carlo Zimarino, Katarzyna Kmiecik, Mustapha Faroudi, Paul Thompson, Mateusz Wydro, Francisca Wollerton, Carlos Gaspar, Mihriban Tuna. F-star Biotechnology Ltd., Cambridge, United Kingdom. B092 Therapeutic targeting of tumorigenic EphA2+/EphA3+ brain tumor initiating cells with bi-specific antibody in glioblastoma. Parvez Vora

1, Maleeha Qazi

1, Chirayu Chokshi

1, Chitra Venugopal

1, Max London

2, Amy

Hu2, Nicole McFarlane

1, Minomi Subapanditha

1, Mohini Singh

1, Sujeivan Mahendram

1, Jarrett Adams

2, Jason

Moffat2, Sachdev Sidhu

2, Sheila Singh

1.

1McMaster University, Hamilton, ON, Canada;

2University of Toronto,

Toronto, ON, Canada. B093 In vitro testing solid cancers immunotherapy protocols through impedance technology allows dynamic and label-free evaluation of immune response and reagent efficacy. Fabio Cerignoli, Biao Xi, Garret Guenther, Trent Rector, Lincoln Muir, Leyna Zhao, Yama Abassi. ACEA Biosciences Inc., San Diego, CA. B094 Targeted expression and molecular profiling assay for tumor microenvironment. Alex Chenchik, Andrey Komarov, Michael Makhanov, Sunitha Sastry, Costa Frangou. Cellecta, Inc., Mountain View, CA. B095 Multiplexed detection of RNA and proteins on the nCounter® platform with low sample input protocol. Sarah Warren, Gary Geiss, Brian Burditt, Qian Mei, Alan Huang, Maribeth Eagen, Eduardo Ignacio, Dwayne Dunaway, Lucas Dennis, Joseph Beechem. NanoString Technologies, Seattle, WA. B096 Optogenetics-based dissection of chemotactic signaling in neutrophils. Brian R. Graziano

1, Delquin Gong

1,

Karen E. Anderson2, Orion D. Weiner

1.


2The Babraham Institute, Babraham, Cambridge,

United Kingdom. B097 Analyze and recover functionally defined single immune cell clones through Opto-Electro-Positioning technology. Xiaohua Wang, Yelena Bronevetsky, Guido Stadler, Kristin Beaumont, Xiaoyan Robert Bao, Saki Shimizu, Duane Smith, Kevin Chapman. Berkeleylights Inc, Emeryville, CA.



B098 A panel of well characterized syngeneic models for in vivo screening analysis: MuScreen

TM. Ying Jin, Lan

Zhang, Juan Zhang, Eric Murphy, Zhongliang Li, Meng Qiao, Qian Shi. Crown Biosciences, Taicang, China. B099 The UniCAR system: Inducible CAR T cells for precise reactivity and high efficacy against hematopoietic malignancies. Simon Loff

1, Malte v. Bonin

2, Josephine Dietrich

3, Jan-Erik Meyer

3, Anja Feldmann

4, Claudia Arndt

4,

Johannes Spehr3, Cordula Gründer

1, Gerhard Ehninger

2, Michael P. Bachmann

4, Armin Ehninger

1, Marc Cartellieri

3.

1GEMoaB monoclonals GmbH, Dresden, Germany;

2Medical Clinic and Policlinic I, University Hospital Carl Gustav

Carus, Dresden, Germany; 3Cellex Patient Treatment GmbH, Dresden, Germany;

4Institute of Radiopharmaceutical

Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany. B100 An intrinsic safeguard for chimeric antigen receptor adoptive T-cell immunotherapies. Julien Valton. Cellectis.Inc, New York, NY. B101 Mechanism of T cell activation by phase separation. Xiaolei Su

1, Jonathon Ditlev

2, Enfu Hui

1, Michael

Rosen2, Ronald Vale

1.


2UT Southwestern Medical Center, Dallas, TX.

B102 A microengineered human lymph node-on-a-chip to study cancer immunotherapy. Girija Goyal

1, Donald

Ingber2.

1Harvard University, Cambridge, MA;

2Wyss Institute, Harvard University, Cambridge, MA.

B103 Intralesional administration of CTLA-4 blocking monoclonal antibodies as a means to optimize bladder cancer therapy. Luuk van Hooren

1, Linda Sandin

1, Igor Moskalev

2, Peter Ellmark

3, Anna Dimberg

1, Peter Black

2,

Thomas H. Tötterman1, Sara M. Mangsbo

1.

1Uppsala University, Uppsala, Sweden;

2University of British Columbia,

Vancouver, BC, Canada; 3Alligator Bioscience AB, Lund, Sweden.

B104 Impact of PD-1 blockade on epigenetic and transcriptional reprogramming of exhausted T cells. Kristen E. Pauken

1, Morgan A. Sammons

1, Pamela M. Odorizzi

1, Sasi K. Manne

1, Jernej Godec

2, Omar Khan

1, Debattama Sen

2,

Makoto Kurachi1, R. Anthony Barnitz

2, Bertram Bengsch

1, Alexander C. Huang

1, Jason M. Schenkel

3, Golnaz

Vahedi1, W. Nicholas Haining

2, Shelley L. Berger

1, E. John Wherry

1.


2Harvard Medical School, Boston, MA;

3University of Minnesota, Minneapolis, MN.

B105 HSP90 inhibitor, ganetespib, enhances responses to cancer immunotherapy through increased expression of interferon response genes. Rina M. Mbofung

1, Jodi A. McKenzie

1, Shruti Malu

2, Chengwen Liu

1,

Weiyi Peng1, Isere Kuiatse

1, Leila Williams

1, Seram Devi

1, Zhe Wang

1, Trang Tieu

1, Tim Heffernan

1, Richard E. Davis

1,

Rodabe Amaria1, Patrick Hwu

1.


2Dana Farber Cancer Institute, Boston,

MA. B106 Substantial enrichment of HIV- resistant CD4 T cells by combining the targeted integration of a resistance-cassette at the CCR5 locus with chemoselection. Biswajit Paul

1, Guillermo Romano Ibarra

2, David J.

Rawlings2, Hans-Peter Kiem

1.

1Fred Hutch, Seattle, WA;

2Seattle Childrens Research Institute, Seattle, WA.

B107 Immunotransplant: Merging checkpoint blockade and T-cell transfer into lymphodepleted recipients. Netonia Marshall, Thomas Marron, Judith Agudo, Brian Brown, Joshua Brody. Ichan School of Medicine, Mt. Sinai Hospital, New York, NY.



B108 The HDAC inhibitor HBI-8000 enhances immunotherapy with either PD-1 or PD-L1 blockade in the MC38 model of colon cancer. Reid P. Bissonnette, Alain Rolland, Bob Goodeneow, Mireille Gillings. HUYA Bioscience International, San Diego, CA. B109 Epigenetic reprogramming of T-cells from metastatic melanoma patients enhances central memory and decreases Th2/Treg phenotypes. Andressa L. Sodre

1, David M. Woods

1, Amod Sarnaik

2, Brian C. Betts

2, Jeffrey S.

Weber1.

1NYU Langone Medical Center, New York, NY;

2Moffitt Cancer Center, Tampa, FL.

B110 Topoisomerase I inhibitors enhance efficacy of immunotherapy through a p53 regulatory pathway. Jodi A. McKenzie

1, Rina M. Mbofung

1, Shruti Malu

2, Rodabe N. Amaria

1, Emily L. Ashkin

1, Seram N. Devi

1, Weiyi Peng

1,

Leila J. Williams1, Richard E. Davis

1, Jason Roszik

1, Trang N. Tieu

1, Timothy Heffernan

1, Patrick Hwu

1.

1University of

Texas MD Anderson Cancer Center, Houston, TX; 2Dana-Farber Cancer Institute, Boston, MA.

B111 HDAC inhibitors modulate immune checkpoint blockade in breast cancer. Manuela Terranova Barberio

1,

Scott Thomas1, Niwa H. Ali

1, Jeenah Park

1, Michael D. Rosenblum

1, Alfredo Budillon

2, Pamela N. Munster

1.

1University of California San Francisco, San Francisco, CA;

2National Cancer Institute - G. Pascale, Naples, Italy.

B112 Targeting immunotherapy to the tumor microenvironment using anti-PDL1 VHH. Michael Dougan

1, Jessica

Ingram1, Hidde Ploegh

1, Stephanie K. Dougan

2.

1Whitehead Institute for Biomedical Research, Cambridge, MA;

2Dana-Farber Cancer Institute, Boston, MA.

B113 Translational studies demonstrate that treatment with anti-PD-1 in unresponsive tumors can be improved by enhancing T cell activation in the tumor microenvironment with vaccine based immune therapy. Genevieve Weir

1, Olga Hrytsenko

1, Richard van der Jagt

2, Matthew Cheung

3, Rena Buckstein

3, Tara

Quinton1, Lisa MacDonald

1, Rita Nigam

1, Marc Mansour

1, Neil L. Berinstein

3, Marianne Stanford

1.

1Immunovaccine

Inc., Halifax, NS, Canada; 2Ottawa Hospital Research Institute, Ottawa, ON, Canada;

3Sunnybrook, Toronto, ON,

Canada. B114 Innate immunity modulators to enhance oncolytic VSV-GP for the treatment of ovarian cancer. Janine Kimpel

1, Carles R. Urbiola

1, Catherine Dold

1, Christian Marth

1, Alexander Muik

2, Dorothee Holm-von Laer

1, Guido

Wollmann1.

1Medical University Innsbruck, Innsbruck, Austria;

2Paul Ehrlich Institute, Langen, Germany.

B115 Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Jing Liu

1, Stephen Blake

1, Michelle Yong

1, Heidi Harjunpaa

1, Shin Foong Ngiow

1, Kazuyoshi Takeda

2,

Arabella Young1, Stacey Allen

1, Mark J. Smyth

1, Michele WL Teng

1.

1QIMR Berghofer Medical Research Institute,

Brisbane, Australia; 2Juntendo University, Tokyo, Japan.

B116 Immunovirotherapy in combination with immune checkpoint inhibitors for treating glioblastoma. Dipongkor Saha, Robert Martuza, Samuel Rabkin. Massachusetts General Hospital and Harvard Medical School, Boston, MA. B117 Evaluating the in vitro effects of tumor-treating fields on T-cell responses. Gil Diamant, Ilan Volovitz, Zvi Ram. Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.



B118 Using a high throughput T-cell cytotoxicity assay to develop combination strategies for immunotherapy. Leila Williams

1, Shruti Malu

2, Jodi McKenzie

1, Rina Mbofung

1, Jason Roszik

1, Patrick Hwu

1.

1MD

Anderson Cancer Center, Houston, TX; 2Dana Farber Cancer Institute, Boston, MA.

B119 Characterization of a phosphatidylserine, TAM receptor (Tyro3, Axl, Mertk), PDL1 axis in breast cancer. Canan Kasikara

1, Sushil Kumar

1, Ke Geng

1, Viral Davre

1, Cyril Empig

2, Bruce Freimark

2, Michael Gray

2, Kyle

Schlunegger2, Jeff Hutchins

2, Sergei V. Kotenko

1, Raymond B. Birge

1.

1Rutgers, New Jersey Medical School, Newark,

NJ; 2Peregrine Pharmaceuticals, Tustin, CA.

B120 Synergistic potentiation of the anti-metastatic effect of anti EGFR mAbs by its combination with immunotherapies targeting the ganglioside NGcGM3. Addys Gonzalez, Rances Blanco, Adriana Carr, Kalet Leon. Center of Molecular Immunology, Habana, Cuba. B121 Oncogenic MYC contributes to tumor super-enhancers via eRNA amplification. Yang Eric Guo, Michael Seyffert, Brian Abraham, Xiong Ji, Richard Young. Whitehead Institute MIT, Cambridge, MA. B122 Molecular mechanism of V(D)J recombination from synaptic RAG1-RAG2 complex structures. Heng Ru

1,

Melissa G. Chambers2, Tian-Min Fu

1, Alexander B. Tong

1, Maofu Liao

2, Hao Wu

1.

1Department of Biological

Chemistry and Molecular Pharmacology, Harvard Medical School; Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA;

2Department of Cell Biology, Harvard Medical School, Boston, MA.

B123 Engineering phagocytic signaling. Adam Williamson, Ron Vale. UCSF, San Francisco, CA. B124 Roles for Tnfsf11 expression by group 3 innate lymphoid cells. Jennifer K. Bando

1, Christina Song

2, Susan

Gilfillan1, Marco Colonna

1.

1Washington University School of Medicine, St. Louis, MO;

2AbbVie, Redwood City, CA.

B125 The relationship between members of the canonical NF-κB pathway, components of the microenvironment and survival in patients with colorectal cancer. Jean A. Quinn, Lindsay Bennett, Antonia Roseweir, James H. Park, Paul G. Horgan, Donald C. McMillan, Joanne Edwards. University of Glasgow, Glasgow, United Kingdom. B126 Correlation of tumor growth inhibition by check point inhibitors with PD-L1 expression in preclinical patient derived xenograft (PDX) models. Maria Stecklum, Annika Wulf-Goldenberg, Bernadette Brzezicha, Iduna Fichtner, Jens Hoffmann. EPO GmbH, Berlin, Germany. B127 Free DNA and tolerance. Gilberto Filaci, Francesca Ferrera, Samuele Tardito, Tiziana Altosole, Cinzia Bernardi, Alessia Parodi, Daniela Fenoglio. University of Genoa, Italy, Genova, Italy. B128 Clinical translation of oncolytic measles virus for T cell activation. Christine E. Engeland, Rū V d , Christof von Kalle, Dirk Jaeger, Guy Ungerechts. National Center for Tumor Diseases, Heidelberg, Germany. B129 Multiple immune checkpoint receptors are co-expressed on tumor antigen-specific T cells and contribute to tumor immune evasion. Robert J. Durso, Jerry Pei, Michelle Russell, Pratha Budhani, Elena Burova, Chandrika Taduriyasas, Ella Ioffe, Markus Mohrs, Gavin Thurston, Jie Dai. Regeneron Pharmaceuticals, Inc., Tarrytown, NY.



B130 Dysregulated Toll-like receptor responses as an oncogenic driver. Olivia Majer, Bo Liu, Angus Yiu-fai Lee, Greg Barton. University of California, Berkeley, Berkeley, CA. B131 Quantitative modeling of Syk regulation in B cell chronic lymphocytic leukemia. Maria P. Frushicheva. Massachusetts Institute of Technology, Cambridge, MA. B132 Importance and mechanism of poly(A) tail length-mediated translational control in different immune cells. Kehui Xiang, David Bartel. Whitehead Institute for Biomedical Research, Cambridge, MA. B133 Regulation of antiviral immune responses by RNase L. Jonathan Clingan

1, Sterling Eckard

1, Daphne

Cooper2, Hilario Ramos

1, Jaime Guillen

3, Bruno Canard

3, Michael Gale, Jr.

1, Jay Hesselberth

2, David Barton

2, Daniel

Stetson1.

1University of Washington, Seattle, WA;

2University of Colorado School of Medicine, Aurora, CO;

3Aix-

Marseille Universite, Marseille, France. B134 Cryo-EM structure of the activated NAIP2-NLRC4 inflammasome reveals nucleated polymerization. Liman Zhang

1, Shuobing Chen

2, Jianbin Ruan

1, Liron David

1, Youdong Mao

3, Hao Wu

1.

1Boston Children's hospital, Boston,

MA; 2Peking University, Beijing, China;

3Dana-Farber Cancer Institute, Boston, MA.

B135 Chemotherapy for esophageal cancer: Off-target effect and biomarker. Tomohira Takeoka

1, Kumiko

Goto2, Mitsunobu Matsumoto

2, Yasuhiro Miyazaki

1, Tomoki Makino

1, Tsuyoshi Takahashi

1, Yukinori Kurokawa

1,

Makoto Yamasaki1, Shuji Takiguchi

1, Masaki Mori

1, Yuichiro Doki

1, Hisashi Wada

1.

1Graduate School of Medicine,

Osaka University, Osaka, Japan; 2Shionogi & CO., Ltd, Osaka, Japan.

B136 Checkpoint blockade and costimulation to treat the transmissible Tasmanian devil facial tumor. Andrew S. Flies

1, John D. Hayball

2, A. Bruce Lyons

1, Greg M. Woods

1.

1University of Tasmania, Hobart, Australia;

2University

of South Australia, Adelaide, Australia. B137 Establishment of a variety of primary mouse tumor allografts of defined disease pathways for evaluating immunotherapy. Jiagui Qu, Davy Ouyang, Annie An, Henry Li. Crown Biosciences, Santa Clara, CA. B138 Immunotherapy effect on survival of acute myeloid leukemia patients. Runhua Shi

1, Teena Li

2, Lawrence

Shi3, Glenn Mills

1.

1LSU Feist-Weiller Cancer Center, Shreveport, LA;

2LSU, Baton Rouge, LA;

3Caddo Parish Magnet

High School, Shreveport, LA. B139 Polyrotaxane based carrier system with mobile targeting ligands for enhanced active targeting in circulatory environment in vivo. Donghyun Jang, Won Jong Kim. POSTECH, Gyeongsangbuk-do, Korea, Republic of. B140 Autologous human growing tumor model and its immunological relevance for cancer immunology research. Seung Chul Heo, Sang Mok Lee, Beonghoon Sohn, Ji-Eun Kim, Rumi Shin. Boramae Medical Center, Seoul, Korea, Republic of. B141 Targeting the complement system to improve radiation treatment. Monica M. Olcina, Amato J. Giaccia. Stanford University, Stanford, CA. B142 Long non-coding RNA expression during CD8

+ T cell differentiation and exhaustion. William Hudson,

Haydn Kissick, Masao Hashimoto, Rafi Ahmed. Emory University, Atlanta, GA.



B143 Fc gamma receptor IV mediated depletionof tumor infiltrating regulatory T cells by anti-CTLA4 antibody is promoted byTLR1/2 agonist and hence its efficacy in anti-tumor combination therapy. Naveen Sharma, James P. Allison. The UT MD Anderson Cancer Center, Houston, TX. B144 Elucidating germinal center B cell metabolic states and their influence on selection. Harald Hartweger, Shlomo Finkin, Michel C. Nussenzweig. The Rockefeller University, New York, NY. B145 Small molecule inhibition of cyclic GMP-AMP synthase reduces interferon expression in macrophages from an autoimmune mouse model. Pu Gao. Memorial Sloan Kettering Cancer Center, New York, NY.

Poster Session A Sunday, September 25 5:00 p.m. … Documents/IMM16_AbstractTitles.pdf · Sebastian...

Documents

Transcript of Poster Session A Sunday, September 25 5:00 p.m. … Documents/IMM16_AbstractTitles.pdf · Sebastian...